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Striatal Dopamine Release by Serotonergic Terminals in the Dopamine-Depleted Rat
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Parkinson’s disease (PD) results from severe dopamine (DA) neuron loss within the
substantia nigra pars compacta. In an effort to replace the diminished DA levels, L-dopa,
the precursor of DA, is administered. Although the most commonly prescribed medication,
the site(s) where L-dopa is converted to DA is not well understood. Three likely striatal
sites meeting the requirement of amino acid decarboxylase presence include remaining
dopaminergic neurons, serotonergic terminals, and striatal intemeurons.
Studies have shown that serotonin (5-HT) neurons are capable of DA synthesis
following exogenous L-dopa administration. In addition, striatal hyperinnervation by
serotonergic dorsal raphe nucleus (DRN) axon terminals occurs following prolonged DA
depletion. This dissertation tests the hypothesis that the serotonergic system is the major
site where DA is synthesized from exogenous L-dopa in the DA-depleted rat.
The neurotoxins 6-hydroxydopamine, 5,7-dihydroxytryptamine, and quinolinic acid
were intracerebrally injected in rats to address dopaminergic terminals, serotonergic
terminals, and striatal intemeurons, respectively, as possible sites of DA production from
exogenous L-dopa. Using microdialysis, in vivo measurements of extracellular DA were
made during 4 conditions: basal release, under DRN stimulation, basal release in the

xm

presence of administered L-dopa, and concurrent with DRN stimulation subsequent to Ldopa treatment. DA concentration in the dialysate was determined using high-performance
liquid chromatography with electrochemical detection.
In this study, the hypothesis that serotonergic terminals are the major contributors
to striatal DA release following exogenous L-dopa administration was tested in rats having
severe, prolonged DA depletion. First, DA release was significantly increased in DAdepleted rats following DA-denervation. Stimulation of the serotonin afferents resulted in
further increased DA release. Removal of the serotonergic terminals in DA-denervated rats
removed the increased basal and stimulation-evoked DA release. Application of a selective
serotonin reuptake inhibitor reduced the basal and stimulation-evoked DA release but not
nearly as much as the DA and 5-HT-depleted animals. Basal and stimulation-evoked DA
release was minimally reduced with removal of striatal intemeurons in DA-depleted rats.
These results suggest that striatal DA release following exogenous L-dopa administration
in rats with severe, prolonged DA depletion occurs primarily from serotonergic nerve
terminals where as striatal intemeurons are only minor contributors.
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CHAPTER ONE
INTRODUCTION AND REVIEW OF THE STRIATUM AND PARKINSON’S
DISEASE

Parkinson’s disease (PD) was first described in 1817 by Dr. James Parkinson in his
“Essay on the Shaking Palsy” where he describes patients with resting tremor, increased
muscle tone, and difficulty initiating movement [reviewed in 16]. It was not until the early
1900s that investigators determined depigmentation in an area of the midbrain called the
substantia nigra pars compacta (SNc) among parkinsonian patients [reviewed in 2]. These
pigmented cells were later found to synthesize dopamine (DA) [reviewed in 2]. The
identification of DA deficiency in the disease resulted in attempts to replenish the
transmitter through administration of its precursor levodopa, or L-dopa.
Although L-dopa is the most effective and potent drug available to alleviate patients
of their debilitating symptoms, it does not inhibit the progression of the disease [reviewed
in 2, 16, reviewed in 75]. It is not fully understood why patients eventually become
unresponsive to L-dopa in later stages of the disease. The decline in L-dopa responsiveness
may be attributable to degeneration of remaining DA neurons, the presumed site of L-dopa
conversion. However, in many patients L-dopa remains effective for many years,
suggesting that alternative non-dopaminergic sites within the brain may be capable of
converting exogenous L-dopa to DA.
In an effort to determine the most probable site(s) of DA synthesis from its
administered precursor, this dissertation evaluates each possibility to determine their likely
contribution in rats with severe DA depletion. This introduction provides the foundation
and rationale for the sites investigated, descriptions of the mechanisms of actions of
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neurotoxins utilized to produce specific neurotransmitter deficiencies, and the methodology
selected for in vivo measurements of DA release utilized in experiments described in
subsequent chapters.

2

1. Summary
PD results from a loss of DA-containing neurons within the SNc. L-dopa, the
precursor of DA, is the most common therapy for PD patients. However, the site of L-dopa
uptake and conversion to DA is not well understood. This dissertation proposes that dorsal
raphe serotonergic terminals that heterotypically sprout into the DA-denervated striatum
are primarily responsible for DA synthesis from applied L-dopa.

1.1 General Hypothesis
• Striatal serotonergic terminals are the predominant site where DA synthesis occurs from
exogenous L-dopa in the parkinsonian rat model.

1.2 Specific Hypotheses
• DA release subsequent to exogenous L-dopa application is increased following
prolonged DA depletion in the DA-denervated rat.
• DA release following exogenous L-dopa administration is reduced in the DA-depleted
rat also deficient of striatal serotonin (5-HT).
• DA release following L-dopa therapy is reduced in the DA-depleted rat also deficient of
striatal intemeurons.
• Striatal DA release subsequent to administered L-dopa is reduced in DA-depleted rats
treated with a selective serotonin reuptake inhibitor.

3

2. The Striatum
The striatum, or neostriatum, consists of two subcortical nuclei, the caudate nucleus
and the putamen, both critical in the regulation of voluntary movement. One of the defining
characteristics of the striatum is the presence of striosomes, or patches. These regions are
devoid of acetylcholinesterase, but contain large quantities of neuropeptides and opiate
receptors. The remainder of the striatum, the matrix, is highly concentrated with
acetylcholinesterase.
Striatal neuronal populations are classified into two groups with respect to the
presence or absence of dendritic spines, spiny and aspiny, respectively [3, 4, 9, 21, 36, 77].
The striatum predominantly consists of medium spiny neurons, the only striatal efferent
projection neurons. These cells provide inhibitory and neuromodulatory actions as a result
of the intracellular presence of gamma butyric acid (GABA), substance P, enkephalin,
dynorphin, transforming growth factor a, or calbindin-D28K [3, 15, 21, 77]. Since
spontaneous action potentials rarely occur in striatal spiny neurons, they require activation
by striatal afferents in order to mediate their modulating effect [77].
The second population, the large, aspiny intemeurons, contain somatostatin,
neuropeptide Y, NADPH-diaphorase, acetylcholine, vasoactive intestinal polypeptide,
cholescystokinin, or GABA [15, 21]. They can be subdivided into three groups according
to their electrophysiologic characteristics (fast-spiking, low-threshold spikes, and longlasting after-hyperpolarizing) [9, 15, 36, 77]. Although the highest concentration of
acetylcholine in the mammalian brain is located within the striatum [24, 58], aspiny
intemeurons are estimated to account for only 1 to 4% of the striatal neuronal population
[4, 14,15, 58]. These intemeurons play a significant role in normal striatal function in
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addition to the regulation of motor control through their contacts with afferents from the
SNc and the projection neurons making up the striatal pathways [9, 28].
The major afferent innervation of the striatum originates from the cerebral cortex.
In addition, dopaminergic and serotonergic pathways from the SNc and dorsal raphe
nucleus (DRN), respectively, innervate the striatum [5, 29, 32, 63, 66, 72].
Electrophysiological studies have shown that both pathways converge upon the same
neurons within the striatum [19], but serotonergic density within the striatum is much lower
than dopaminergic density. However, the ventral striatum contains a greater density of
serotonergic innervation in comparison to the dorsal striatum [42, 66]. The noradrenergic
locus ceruleus neurons also innervate the striatum, but to a much lesser degree than either
dopaminergic or serotonergic projections [49],

3. Hyperinnervation of the DA-Denervated Striatum
There is substantial evidence to support the occurrence of striatal serotonergic
hyperinnervation 2 to 9 months following DA denervation using 6-OHDA in neonatal rats
[1, 11, 12, 30, 39, 42, 51, 59, 63, 64, 71]. Immunohistochemical analysis reveals an
increase in 5-HT fiber density without increased 5-HT turnover [42]. Similar results have
also been reported in adult mice treated with MPTP [62]. Contradictory findings, however,
have been observed among adult rats subsequent to DA denervation during adult life with
reported results ranging from an increase [26, 80] to a decrease [49, 67]. The difference
between the studies in adult rats is the time between the 6-OHDA lesion and subsequent
analysis. Both Guerra et al. [26] and Zhou et al. [80] waited 2 to 4 months post-DA
denervation. Studies failing to see 5-HT hyperinnervation waited only 2 weeks which did
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not allow sufficient time for neuroplastic changes in response to the lesion to take place. It
is not surprising that their results differed from prior investigations.
The trigger for proliferation of serotonergic fibers has been postulated to be the
extensive DA fiber loss since 5-HT innervation did not increase until there was 95% striatal
DA neuron loss as determined by immunohistochemical techniques [1, 26, 39, 42, 62, 66,
71, 80]. This is further supported by observations demonstrating a large increase in
serotonergic fiber density within the dorsal striatum in sharp contrast with the normal
pattern where DA innervation predominates [42, 66]. These findings suggest that the
collateral sprouting of dorsal raphe afferents into the DA-denervated striatum result from
the diminished competition with nigrostriatal dopaminergic afferents for synaptic sites [64].
However, DA-rich intrastriatal transplants do not preclude striatal serotonergic
hyperinnervation in neonatal [1] or adult DA-lesioned rats [26]. In fact, the presence of a
nigral graft before or following DA denervation of the striatum does not affect the 5-HT
sprouting response.
The possibility that neurotrophic factors may be involved in serotonergic
hyperinnervation has also been postulated [1]. Numerous studies have investigated survival
of nigral neurons or grafts in DA-lesioned animals with treatment of glial cell line-derived
neurotrophic factor (GDNF) [37,44, 61,78], transforming growth factors-(3s [22], Nterminal tripeptide of insulin-like growth factor (IGF)-l [25], and brain-derived
neurotrophic factor (BDNF) [73]. Although all of these neurotrophic factors appear to
protect dopaminergic neurons from 6-OHDA neurotoxicity, it is not known whether their
endogenous release contributes to the ability of 5-HT terminals to hyperinnervate the
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striatum subsequent to severe DA depletion. More studies are necessary to further
investigate the mechanisms involved in this plasticity response.
Striatal serotonergic hyperinnervation has not, to our knowledge, been investigated
in the human brain with PD. However, it is logically conceivable that some type of “new”
innervation occurs since it is well established that the brain is capable of changing or
adjusting in response to insult. The relevance of 5-HT hyperinnervation of the DAdenervated striatum is investigated in this dissertation in an attempt to explain why PD
patients become unresponsive to L-dopa treatment and experience symptoms of 5-HT
depletion (e.g., depression, mood disorders, sleep abnormalities, anxiety, dementia)
[reviewed in 2, reviewed in 16, 45, reviewed in 75] with disease progression.

4.

Neuropathology of Parkinson’s Disease
In PD, there is a loss of pigmented cells that contain the neurotransmitter DA within

the SNc, but the cause of this loss is not understood. Marked depletion of DA neurons is
replaced by extensive gliosis within the SNc [reviewed in 16, 17, 20, 23,47]. In many of
the remaining dopaminergic neurons, eosinophilic cytoplasmic inclusions called Lewy
bodies accumulate [reviewed in 16, 17, 20, 23, 47]. Also, extracellular concentrations of
melanin released from the degenerating DA neurons vary [reviewed in 16, 17, 20, 23, 47].
Although DA neurons appear to be the primary target in the disease, additional
neuronal populations are also affected. Locus ceruleus noradrenergic neurons, 5-HT cells
of the raphe nucleus, and acetylcholine-containing neurons located in the nucleus basalis of
Meynert are also reduced in number [reviewed in 16, 47]. In addition, DA projections to
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the nucleus accumbens and ventral tegmentum are also diminished, but to a much lesser
degree than those innervating the striatum [reviewed in 16, 47].

5. Neurochemistry of Parkinson’s Disease
As a result of the severe DA depletion, patients exhibit classical symptoms such as
resting tremor, bradykinesia, increased muscle tone, and postural instability [reviewed in 2,
reviewed in 16, reviewed in 75]. The abnormal motor functioning is a consequence of the
diminished interactions of the SNc with the basal ganglia, a group of subcortical nuclei that
function in voluntary movement [reviewed in 2]. To understand the symptoms of the
disease, examination of the basal ganglia circuitry is critical. An anatomical and functional
model depicting the basal ganglia circuitry currently exists (Figure 1). However, it should
be considered a working model, as some debate exists regarding some of the
interconnections [40, 57, reviewed in 75].
Input to the basal ganglia occurs through the striatum (i.e., the caudate and
putamen) primarily from the cerebral cortex. Information is then channeled through
additional structures before reaching the substantia nigra pars reticularis (SNr) and internal
segment of the globus pallidus (GPi), the output nuclei of the basal ganglia. Two proposed
pathways, the direct and indirect, determine the structures involved in the transmission of
information to the output nuclei (Figure 1). The direct pathway channels information
uninterrupted from the input nuclei (the striatum) to the output structures of the basal
ganglia (SNr and GPi). On the other hand, signals transmitted via the indirect pathway goes
through the external segment of the globus pallidus (GPe) and the subthalamic nucleus
(STN) before reaching the GPi or SNr.
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When there is a deficiency of DA, as in PD, less neurotransmitter is available to
interact with postsynaptic DA receptors located on striatal neurons (Figure 2). With respect
to the direct pathway, there is less excitation via Di receptors located on GABAergic
striatal projection neurons resulting in reduced inhibition of the basal ganglia output nuclei.
Consequently, the thalamus and pedunculopontine nucleus (PPN) are overly inhibited.
Although the indirect pathway utilizes D2 receptors and communicates with the
output nuclei via two additional structures, the end result is the same. The decreased level
of DA within the SNc results in less DA available to react with D2 receptors on
GABAergic projections. As a consequence of these projection neurons being more active
than normal, there is less inhibition of the subthalamic nucleus which in turn over
stimulates the output nuclei. The result is over-inhibition of the thalamus and PPN.
In an effort to replenish the neurotransmitter deficiency of PD, the DA precursor, Ldopa, is utilized clinically to balance the basal ganglia circuitry. L-dopa and its use in the
treatment of PD will be discussed in detail later in this chapter.
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Figure 1. A generally accepted model of the basal ganglia circuitry in a normal individual.
Input to the thalamus and pedunculopontine nucleus (PPN) from the basal
ganglia is modulated by striatal control of the internal segment of the globus
pallidus (GPi) and the substantia nigra pars reticularis (SNr). Transmission of
information from the striatum can occur through two pathways: direct and
indirect. Signals channeled uninterrupted to the output nuclei (GPi and SNr)
depict the hypothesized direct pathway. Striatal communication using the
external segment of the globus pallidus (GPe) and the subthalamic nucleus
(STN) before reaching GPi and SNr describe the indirect pathway. SNc,
Substantia nigra pars compacta; GABA, gamma butyric acid; Dyn, dynorphin;
Sub P, substance P; Enk, enkephalin.
high)
(Pathway activity:....very low, — low, ^normal,
(+ depicts excitatory and - represents inhibitory).
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PPN

Figure 2. A generally accepted model of the basal ganglia circuitry in Parkinson’s disease.
The thalamus and pedunculopontine nucleus (PPN) are over-inhibited as a result
of altered basal ganglia output. With less DA available to react with the postsynaptic striatal DA receptors, the basal ganglia output nuclei (i.e., internal
segment of the globus pallidus (GPi) and the substantia nigra pars reticularis
(SNr)), are less inhibited and over-stimulated via the direct and indirect
pathways, respectively. SNc, Substantia nigra pars compacta; GABA, gamma
butyric acid; Dyn, dynorphin; Sub P, substance P; Enk, enkephalin.
(Pathway activity:....very low, — low, “"normal, WM high)
(+ depicts excitatory and - represents inhibitory).
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6. Levodopa (L-dopa) Treatment in Parkinson’s Disease
The most effective drug available to treat PD is L-dopa, the precursor of DA.
Although L-dopa does not slow the disease progression, it acts to reverse the symptoms for
a period of time by replenishing DA. However, the response to L-dopa declines with the
progression of the disease. Whether the treatment becomes ineffective because of continual
progressive DA neurodegeneration or due to the toxicity of L-dopa remains to be answered.

6.1 Possible Sites of Conversion
The site(s) where the DA synthesis takes place from the administered L-dopa is not
well understood. The conversion of L-dopa depends on the presence of the enzyme
aromatic amino acid decarboxylase (AADC). Dopaminergic, serotonergic, and
noradrenergic neurons, all of which innervate the striatum, have been identified to contain
AADC [7, 10, 27, 50, 81]. In addition, AADC has been discovered in nonaminergic
intemeurons, in capillary endothelium, and in glial cells [10, 27, 50, 81]. The presence of
AADC in different cell types provides potential sites for exogenous L-dopa conversion to
DA when the number of DA neurons is severely diminished.

Remaining Dopaminergic Nerve Terminals in the Striatum
It is well established that dopaminergic terminals contain the majority of AADC
[10, 81]. With progression of the disease, this pool of AADC diminishes as more DA
neurons degenerate. Partial compensation for DA loss occurs through hyperactivity of the
remaining DA cells [79]. These remaining cells have been shown to have increased
impulse activity, increased synthesis and release of DA, and a reduction in the number of
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reuptake carriers [52]. Postsynaptic DA receptors are also upregulated [52]. Although an
attempt is made by these neurons to compensate for the severe DA loss, it is unlikely that
they are capable of maintaining this high-energy state for an extended period of time before
they exhaust themselves or succumb to the degenerative process of the disease. The
presence of AADC in non-dopaminergic cells suggests possible alternative sites of DA
synthesis as a “back-up mechanism” in the event of severe DA depletion.

Serotonergic Nerve Terminals in the Striatum
The synthesis of 5-HT from its precursor, 5-hydroxytryptophan (5-HTP), also
requires AADC [7, 10, 49, 54, 55, reviewed in 75, 81]. AADC involved in the production
of 5-HT and DA has been determined to be identical [41, 50, 81]. Furthermore, 5-HT
neurons have been shown to contain DA following exogenous L-dopa administration [6,
55,68].
As previously discussed, subsequent to severe DA depletion, striatal serotonergic
hyperinnervation has been documented to occur. The increased number of 5-HT terminals
potentially provides more sites available for DA to be synthesized from exogenous L-dopa.
Together, these findings suggest serotonergic neurons as a likely site for conversion in a
severely DA-depleted animal administered L-dopa.

Noradrenergic Nerve Terminals in the Striatum
AADC has also been detected in noradrenergic neurons [49, reviewed in 75, 81].
Striatal innervation of fibers originating from the locus ceruleus is sparse [49]. Following
6-OHDA lesioning, noradrenergic hyperinnervation has been documented in the
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cerebellum and other brainstem structures, but not in the striatum [38]. This implies that
noradrenergic cells are not likely to contribute significantly to the conversion of DA from
exogenously applied L-dopa.

Striatal Intemeurons
Striatal intemeurons also contain AADC providing yet another potential site for DA
production from exogenous L-dopa. It has been shown that following intrastriatal
application of kainic acid (KA), AADC activity is reduced by approximately 20% [27, 49].
KA is an excitotoxin thought to be selectively toxic to cell bodies rather than terminals or
fibers of passage [56]. If tme, the reduction in AADC activity would be attributable solely
to intemeurons rather than damage to some of the DA terminals. Although striatal
intemeurons provide an alternative site for DA production, it is questionable whether these
intemeurons are sufficient to compensate for the DA neuron loss.

Glial Cells
Glial cells have also been determined to contain AADC [49, 81]. While intrastriatal
application of KA increased glial cell proliferation [27,49, 56], AADC activity decreased
[27]. The enzyme activity was further reduced following DA depletion using 6-OHDA in
addition to intrastriatal application of KA [27]. If glial cells were significantly contributing
to the decarboxylation of L-dopa, then the concentration of DA and its metabolites should
increase rather than decrease following KA injection within the striatum. The decrease in
AADC activity discounts the role of glial cells in the conversion of exogenous L-dopa to
DA.
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Endothelial Cells of Cerebral Microvessels within the Striatum
Although AADC has been identified in endothelial cells of cerebral microvessels
[27, 49, 81], AADC activity within capillaries occurs primarily outside the blood-brain
barrier [49]. Since DA does not cross the blood-brain barrier, DA produced by endothelial
cells would not reach the DA postsynaptic receptors, making them an unlikely candidate
for increased DA content in the striatum.

6.2 Summary of Possible L-dopa Conversion Sites
Based on the current literature, remaining DA terminals, dorsal raphe serotonergic
terminals, and striatal intemeurons provide the most likely sites where exogenous L-dopa
can be converted to DA. This information provided the foundation for the sites investigated
in this dissertation.

7. Neurotoxins Utilized in Animal Models
The discovery of neurotoxins has led to further insight into the etiology of
neurodegenerative diseases. Their identification has provided a means by which regional
deficits within the brain can be produced to mimic characteristics of neuronal pathology
seen in specific diseases which has facilitated therapeutic advancements. Three toxins: 6OHDA, 5,7-dihydroxytryptamine (5,7-DHT), and quinolinic acid (QA) were employed to
investigate the contribution of remaining DA terminals, 5-HT terminals, and striatal
intemeurons, respectively, in the production of DA within the striatum from administered
L-dopa. The mechanisms of action of each toxin will be reviewed in the next section.
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7.1 6-Hydroxydopamine (6-OHDA)
Parkinsonism can be induced in rats by depleting the nigrostriatal dopaminergic
system using 6-OHDA [31, reviewed in 38, 70]. Because of its structural similarity to
catecholamines, 6-OHDA is taken up by high-affinity reuptake systems present in the
plasma membrane of catecholamine-containing neurons. Being highly reactive, it oxidizes
spontaneously to form 6-OHDA-quinone and hydrogen peroxide. Further metabolism
produces the superoxide anion and hydroxyl radical, both of which are extremely damaging
to proteins, lipids, and DNA of cells.
The accumulation of 6-OHDA within neurons is one of two factors that determine
the neurodegenerative effects of 6-OHDA [34, reviewed in 38]. Therefore, the density of
the reuptake receptors determines the amount of toxin that can be accumulated within a cell
at any given location. Reuptake sites are most abundant on the nerve terminals followed by
axons making these regions most susceptible to damage by 6-OHDA. This provides
justification for injection into the medial forebrain bundle (MFB).
The toxic effect of 6-OHDA is also dependent on the formation of pre-cytotoxic
and cytotoxic products [34, reviewed in 38]. Oxidation of 6-OHDA results in the formation
of cytotoxins and oxidized analogs that further facilitate the oxidative process because of
their low reduction potentials. Some of these reactions are catalyzed by metal ions or
complexed metal ions which initiate the autoxidative process. In the absence of metal ions,
oxidation can proceed; however, the reactions may be slowed or delayed by the presence of
superoxide dismutase, a radical scavenging enzyme.
This redox cycling is the most likely mechanism by which 6-OHDA induces its
detrimental effects. Following formation of the cytotoxic or pre-cytotoxic products, cell
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damage may occur from weakening of membrane integrity, loss of cell viability, oxidative
phosphorylation uncoupling, disruption of normal membrane character or function, lipid
peroxidation, apoptosis, disruption of ion pumps, or the reduction of neuronal pH [34,
reviewed in 38].
To produce regional tissue damage within the brain, 6-OHDA must be directly
injected into the brain because it cannot cross the blood-brain barrier. The standard vehicle
consists of 0.9% NaCl and 0.1% ascorbic acid [38]. The addition of ascorbic acid (ie.,
vitamin C) prevents autoxidation of 6-OHDA into its toxic breakdown products. Ascorbic
acid also reduces the oxidized products.
It is important to note that 6-OHDA has a differential specificity for neuron types
[34]. Noradrenergic cells are the most susceptible followed by dopaminergic neurons. 6OHDA also affects serotonin-containing (indolaminergic) neurons, although to a lesser
extent than dopaminergic cells. Adrenergic neurons are the least vulnerable. Dependent
on the experimental goal it may be necessary to administer a reuptake blocker for
noradrenergic and serotonergic neurons when utilizing 6-OHDA. For this dissertation it
was essential to prevent 6-OHDA uptake into both noradrenergic and serotonergic
neurons. This was accomplished by the intraperitoneal administration of desipramine
prior to DA lesioning [34, reviewed in 38].

7.2 5,7-Dihydroxytryptamine (5,7-DHT)
5-HT depletion can be achieved by the administration of the toxin 5,7-DHT.
Because of its structural similarity to 5-HT, it is taken up by the high-affinity receptors
along the membrane of 5-HT-containing neurons. Although 5,7-DHT is highly reactive
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(i.e., oxidizes spontaneously), it must reach a given concentration to induce cellular
damage. Like 6-OHDA, the density of reuptake receptors ultimately determines how
much 5,7-DHT can accumulate within a serotonergic neuron. Because the axons and
nerve terminals of serotonergic neurons contain the greatest number of the high-affinity
receptors, 5,7-DHT was directly injected into the striatum for this dissertation.
It is not known exactly how 5,7-DHT induces its toxic effects. However, as
previously mentioned, it is understood that a critical concentration must be achieved within
the neuron before degeneration can occur. Two hypotheses currently exist to explain how
this toxin exerts its actions. The first involves the production of quinoid products from the
oxidation of 5,7-DHT within serotonergic neurons [34, reviewed in 38]. The highly
reactive metabolites interact with proteins and other macromolecules essential for proper
cell functioning.
The second hypothesis involves the intracellular production of the superoxide
anions, hydrogen peroxide, and the hydroxyl radicals, all of which are cytotoxic reactive
oxygen species [34, reviewed in 38]. Evidence suggests that catalysis of the oxidative
reactions occur as a result of intraneuronal and mitochondrial enzymes. Furthermore,
accumulation of the toxin is likely to occur within the mitochondria disrupting oxidative
phosphorylation.
Induction of central 5-HT deficiency requires direct application of 5,7-DHT to a
specific region within the brain. Ascorbic acid (0.1%) in a sodium chloride (0.9%) solution
is the typical vehicle utilized. Ascorbic acid prevents the oxidation of 5,7-DHT, thus
permitting maximal neuronal depletion for a given volume and concentration of toxin
administered. 5,7-DHT not only affects serotonergic neurons, but it is also taken up by
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noradrenergic cells [18, 34, reviewed in 38]. This was prevented by administering the
noradrenergic reuptake blocker, desipramine [34, reviewed in 38].

7.3 Quinolinic Acid (QA)
QA, pyridine 2,3-dicarboxylic acid, is an excitotoxin capable of activating
excitatory amino acid receptors to produce axon-sparing lesions [33, 65] with generally
good preservation of presynaptic terminals [65]. QA is an endogenous substance
localized in glial cells [33, 65], immune cells [33], and extracellular fluid [65] produced
from the kynurenine pathway during tryptophan metabolism. Although its presence is not
toxic in the normal brain, quinolinic acid can become toxic when present in high
concentrations within the synaptic cleft for extended periods of time [13].
QA is a N-methyl-D-aspartate (NMDA) receptor agonist capable of “exciting”
cells to death, hence its classification as an excitotoxin. NMDA receptors conduct
potassium, sodium, and calcium and overactivation causes calcium accumulation to occur
within the neuron [8, 13, 53, 60, 65]. The increased intracellular calcium leads to the
activation of proteases and lipases, initiating a chain of events ultimately resulting in cell
death [8, 13, 53, 65]. For example, caspase-3 (CPP32) is a protease stimulated by QA
[53]. Once activated, caspase-3 causes the degradation of IkB-oc. Consequently, NF-kB is
also activated causing the death of striatal neurons. Some examples of lipases include
phospholipase A2, arachidonic acid, xanthine oxidase, and nitric oxide, all of which lead
to the generation of free radicals and subsequent neuronal death following activation [8,
53,65].
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The excitotoxic effect of QA is dependent upon three conditions: the initial
depolarization of target neurons, the presence of an intact excitatory amino acid
presynaptic input (e.g., cortico-striatal pathway), and a sufficient concentration of QA
[33, 65]. Theoretically any region of the brain can undergo damage if all conditions are
met. Under normal conditions extracellular QA concentration within the brain is in the
nanomolar range, a level much lower than required to act on the NMDA receptors. When
injected into the striatum, QA results in a focal loss of striatal intemeurons and cell
bodies of efferent neurons, but the inputs into the striatum are not destroyed [33]. This
permitted the use of QA in this dissertation since DA release from striatal afferents is of
interest. Measurement of DA will be discussed in the next section.

8. Microdialysis
Microdialysis is a technique utilized to directly sample the extracellular fluid (ECF)
of living tissue with minimal tissue damage or alteration of fluid balance [34, 43, 69]. This
method was developed from the push-pull perfusion method where fluid was pushed into
and suctioned out of the tissue being sampled. However, in order to prevent blockage in the
tube, high flow rates were necessary ultimately resulting in significant tissue disturbance
and fluid imbalance. Attempts to lower the flow rate were not successful. Also, since the
sample end of the probe was open, large molecules (e.g., enzymes) could be readily taken
up. Consequently, measurement of transmitter concentrations were unreliable and highly
variable.
To eliminate the problems associated with the push-pull technique, a dialysis
membrane was added to the tip of the probe. The presence of the semi-membrane enables
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the technique of microdialysis to utilize the principle of passive diffusion (Figure 3) (see
Appendix 1). This semi-permeable membrane has a low molecular weight cut off which
eliminates the uptake of degradative enzymes and micro-organisms thus making the
samples essentially ultrafiltrates that can be directly analyzed by high-performance liquid
chromatography (HPLC). For those chemicals smaller than the pore size (approximately 10
to 15 kDa), the direction of flow is determined by their concentration gradient.
Measurements can be made in anesthetized and awake animals. For intracerebral
measurements, the “Y”-shaped probe is implanted into the brain and held in place by a
microdrive or cemented in place, depending on the state of the animal. The probe input is
connected to a syringe pump for perfusing artificial cerebrospinal fluid (CSF) through the
probe at a specified rate. Flow rate of the perfusion fluid depends upon the desired probe
recovery. For intracerebral collection, 2 pl/min is appropriate to optimize recovery of the
transmitters of interest (i.e., the concentration of the transmitter in the sample will more
closely approach that of the tissue) [34].
The outside diameter of the membrane is approximately 250 pm and is attached to
the stainless steel tubing of the probe with epoxy. It is critical that the membrane length be
confined within the region being sampled to ensure valid and reliable measurements.
Solutes diffuse down their concentration gradient across the membrane and are collected
from tubing connected to the output arm of the probe. Generally, the samples are collected
in tubes on ice to prevent degradation of the transmitters and can be immediately analyzed
using HPLC or stored at -80°C for later detection.
The use of microdialysis for this dissertation allowed for measurement of striatal
extracellular DA concentrations to be sampled in anesthetized animals. Collection of
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samples were made under several different conditions in an effort to determine the site
where DA conversion from exogenous L-dopa occurs in the DA-denervated rat brain.

24

Figure 3. Schematic diagram of the microdialysis probe.
The microdialysis probe, magnified to show the individual components. The
stainless steel shaft is generally 22 to 25 mm in length with each arm
approximately 8 mm long. The membrane is typically 1 to 4 mm (4 mm in length
was utilized for this dissertation) and approximately 250 pm in diameter for
intracerebral probes, but it ultimately depends upon the structure being sampled.
Optimal flow rate is 2 pl/min. ACSF, artificial cerebrospinal fluid; CSF,
cerebrospinal fluid.
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Abstract
Although L-dopa is used to treat Parkinson’s disease, the site of uptake and
conversion to dopamine (DA) is not well understood. Studies have shown that
serotonergic neuron terminals contain DA following exogenous L-dopa administration. In
addition, hyperinnervation of the striatum (STR) by serotonin (5-HT) neurons has been
revealed immunohistochemically in DA-depleted animals. It is our hypothesis that
exogenous L-dopa is converted to DA by 5-HT terminals that sprout into the DAdepleted STR.
Sprague-Dawley rats were divided into 5 groups: DA-lesioned, DA shamlesioned, DA + 5-HT-lesioned, DA + 5-HT sham-lesioned, and naive controls. Following
pretreatment with desipramine (10 mg/kg, i.p.), DA-depleted and DA + 5-HT-lesioned
rats received a unilateral injection of 6-hydroxydopamine (6-OHDA) (8 (ig 6-OHDA/4
pi ascorbic saline) within the medial forebrain bundle. DA sham-lesioned and DA + 5HT sham-lesioned rats received only the vehicle. After waiting for hyperinnervation to
occur (6-9 months), all animals underwent implantation of a microdialysis probe and a
bipolar stimulating electrode within the STR and dorsal raphe nucleus (DRN),
respectively. One week prior to the implantation procedure, a second surgery was
performed in which 5,7-dihydroxytryptamine (a serotonin neurotoxin) (5,7-DHT) (3 pg
5,7-DHT/2 pi ascorbic saline, 0.9% NaCl with 0.1% ascorbate) or the vehicle were
injected into the STR of the DA + 5-HT-depleted and DA + 5-HT sham-lesioned animals,
respectively. Following the implantation procedure, dialysates were collected during 4
different conditions: basal release, during DRN stimulation, basal release in the presence
of exogenous L-dopa, and concurrent with DRN stimulation subsequent to L-dopa
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administration. DA concentration was determined by high-performance liquid
chromatography with electrochemical detection.
In this study we demonstrate that in DA-depleted rats given L-dopa, basal and
stimulation-evoked DA release were significantly increased when compared to DA shamlesioned, naive control, and DA + 5-HT-lesioned animals. Additionally, in the presence
of L-dopa, DA release was significantly reduced among DA + 5-HT-depleted animals
without and concurrent with DRN stimulation when compared to DA-sham + 5-HT
sham-lesioned, naive control, and DA-lesioned rats. Thus, we conclude that following
prolonged DA depletion, 5-HT terminals that sprout into the STR are responsible for
synthesizing DA from exogenous L-dopa.

37

1. Introduction
Parkinson’s disease (PD) results from a severe loss of dopaminergic neurons
within the substantia nigra pars compacta (SNc). Patients, however, remain asymptomatic
until striatal dopamine (DA) depletion exceeds 80% [18]. The most widely prescribed
medication used in the treatment of PD is L-dopa, but the site(s) for DA synthesis from
exogenous L-dopa is not known. For this to occur, the substrate L-dopa must be taken up
into the neuron terminals and the enzyme responsible for the decarboxylation reaction
converting L-dopa to DA, aromatic amino acid decarboxylase (AADC), must be present
in these terminals.
AADC has been identified in dopaminergic, serotonergic, and noradrenergic
neurons, all of which innervate the striatum (STR) [5, 6, 15, 27, 46]. In addition, it has
also been discovered in nonaminergic intemeurons, in capillary endothelium, and in glial
cells [6, 15, 27, 46]. The presence of AADC in different cell types provides potential sites
where L-dopa could be converted to DA when the number of DA neurons is diminished.
It is well established that striatal dopaminergic terminals contain the majority of
AADC [6, 22, 46]. With progressive nigral degeneration, this pool of AADC also
diminishes. Partial compensation for DA loss occurs through hyperactivity in the
remaining DA cells [44]. It has been reported that in the remaining DA neurons there is
an increase in impulse activity, synthesis and release of DA are increased, and the
number of DA reuptake sites are reduced [30]. Postsynaptic receptors are also
upregulated [30]. However, with more than 80% DA depletion, it is unlikely that the
remaining dopaminergic neurons (which continue to degenerate) can significantly and
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sufficiently increase striatal DA levels for prolonged periods of time to maintain an
asymptomatic state.
A second possible compartment for DA synthesis from exogenous L-dopa is the
serotonergic axon terminals originating from the dorsal raphe nucleus (DRN). The
synthesis of 5-HT from its precursor, 5-hydroxytryptophan (5-HTP), also requires AADC
[5, 6, 27, 32, 46]. It has been determined that the decarboxylating enzyme involved in the
production of 5-HT and DA are identical [22, 29, 46]. Furthermore, serotonergic neurons
have been found to convert the exogenously applied L-dopa to DA [4, 8, 32].
However, there is conflicting evidence regarding DA synthesis in serotonergic
neurons. Melamed et al. [26] have shown that rats with combined dopaminergic and
serotonergic lesions did not differ in DA content following L-dopa administration from
rats having only a DA lesion. Thus, they concluded that serotonergic neurons are not
involved in DA synthesis following exogenous L-dopa application.
Interestingly, striatal serotonergic hyperinnervation through heterotypic axon
sprouting occurs following DA denervation in adult mice [37], neonatal [1, 7, 17, 20, 23,
36, 39, 40, 43] and adult rats [14, 45]. The key to the hyperinnervation is that it does not
occur until at least 95% striatal DA is depleted [45] and requires at least two months post6-OHDA lesion [14, 39, 45] for the establishment of the new innervation pattern. The
study performed by Melamed et al. [26] did not allow sufficient time (only 2 weeks) for
the hyperinnervation to occur. It is likely that had a long enough period of time elapsed,
the significance of the serotonergic system may have been revealed. This is assuming that
the serotonergic neurons, following their hyperinnervation into the STR, convert
exogenously administered L-dopa to DA.
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It is our hypothesis that striatal serotonergic terminals, subsequent to their
hyperinnervation, provide a key site for DA synthesis following L-dopa administration.
In this study we demonstrate a significant increase in basal DA release following L-dopa
treatment among DA-depleted animals relative to sham-lesioned and naive control
animals. Further, depletion of striatal serotonergic terminals in DA-depleted animals
eliminates this increase in basal DA release. These results indirectly suggest that with
prolonged DA loss, significant DA synthesis occurs within striatal 5-HT terminals in the
presence of exogenous L-dopa.

2. Materials and Methods
Thirty-three male, Sprague-Dawley rats (201- 275 g) (Harlan, San Diego, CA)
were divided into 5 different groups: 6-hydroxydopamine (6-OHDA)-lesioned, 6-OHDA
sham-lesioned, 6-OHDA plus 5,7-dihydroxytryptamine (5,7-DHT)-lesioned, 6-OHDA
plus 5,7-DHT sham-lesioned, and naive control. Individually caged animals were housed
in a temperature-controlled room with a 12-hour light-dark cycle with food and water
available ad libitum. Treatment of the rats was in accordance with the Animal Care
Committee of Loma Linda University and the NIH Guide for the Care and Use of
Laboratory Animals.

2.7. Unilateral 6-Hydroxydopamine (6-OHDA) Lesion
The experimental and sham-lesioned groups were administered an intraperitoneal
(i.p.) injection of desipramine dissolved in deionized water (10 mg/kg, Sigma, St. Louis,
MO) forty minutes prior to the first surgical procedure to minimize the ability of
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noradrenergic neurons to take up the 6-OHDA. Each rat was placed in a closed container
under a fume hood with 1/2 ml isoflurane until anesthesia was attained (i.e., not
responsive to toe pinch). The animal was rapidly placed into a stereotaxic frame and
anesthesia was maintained with isoflurane using a pass-by system. An ophthalmic
antibiotic ointment was applied to prevent corneal desiccation during the procedure.
Normal body temperature was maintained during surgery using a heating pad and
periodically checked using a rectal thermometer.
Local anesthesia, bupivacaine HC1 with 0.5% epinephrine (1/2 ml), was applied
subcutaneously (s.c.) at the incision site prior to making a midline incision on the scalp.
The skull was exposed to locate lambda and bregma. The precise coordinates of the
lesion site were determined from the rat atlas of Paxinos and Watson [34].
The experimental groups (N = 13) received an injection of 6-OHDA (8 (Xg 6OHDA/4 pi ascorbic saline, 0.9% NaCl with 0.1% ascorbate, Sigma, St. Louis, MO) at a
rate of 0.2 jxl/min [10, 14] within the left or the right medial forebrain bundle (MFB) (AP
^1.4 bregma, Lat 1.0 midline, V 7.5 dura). Sham-lesioned rats (6-OHDA sham-lesioned
and 6-OHDA plus 5,7-DHT sham-lesioned) (N = 13) received an equal volume of
ascorbic saline in the MFB. Naive control rats (N = 7), did not undergo this surgical
procedure. Three minutes after the completion of the neurotoxin infusion, the needle was
retracted (1 mm/min) and the scalp sutured with nonabsorbable surgical suture.
Following surgery, the rats were returned to their cages, placed under a heat lamp, and
monitored frequently until they ambulated on their own.
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2.2. Apomorphine Testing
Ten to 14 days following surgery, the rats (except the control group) were
administered an injection of apomorphine dissolved in saline (0.20 mg/kg, i.p., Sigma, St.
Louis, MO) [10] to assay the effectiveness of the DA lesioning (Figure 1). Only rats
having 6 or more rotations/min, contralateral to the side of the lesion, over a period of 15
minutes [10] were included in the experimental groups.

2.3. Unilateral 5,7-Dihydroxytryptamine (5,7-DHT) Lesion
Six to 9 months following the 6-OHDA application within the MFB, 7 of the
animals were randomly selected to receive 2 injections of a 5-HT neurotoxin, 5,7-DHT
(Figure 1). To maximize depletion of striatal serotonergic terminals, 5,7-DHT (ICN
Pharmaceuticals, Costa Mesa, CA) was injected into 2 different sites within the STR (AP
+1.0 bregma, Lat 3.0 midline, V 5.2 dura, needle bevel caudally faced and AP -0.4
bregma, Lat 3.05 midline, V 5.2 dura, needle bevel rostrally faced) ipsilateral to the 6OHDA lesion. Forty minutes prior to 5,7-DHT application, desipramine dissolved in
deionized water (10 mg/kg, i.p., Sigma, St. Louis, MO) was administered to protect the
noradrenergic neurons from taking up the toxin. 5,7-DHT (2 injections of 3 jag 5,7DHT/2 pi ascorbic saline, 0.9% NaCl with 0.1% ascorbate) [12] was injected at a rate of
0.2 pl/min. The sham-lesioned animals (N = 7) received an injection of ascorbic saline
equal in volume to that of the neurotoxin. Naive control animals (N = 7) did not undergo
this surgical procedure.
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2.4. Microdialysis Protocol
Dependent on the group, all of the rats underwent microdialysis at one of the
following time points: (1) 6 to 9 months following the 6-OHDA (N = 6) or 6-OHDA
sham (N = 6) lesion, (2) 1 week subsequent to the 5,7-DHT (N = 7) or 5,7-DHT sham (N
= 7) surgery, or (3) 24 to 36 weeks following the arrival of controls (naive) (N = 7). The
animals were prepared for surgery in the same manner as that described for the 6-OHDA
and 6-OHDA sham surgical procedures. A microdialysis probe was implanted into the
STR (AP +0.11 bregma, Lat 2.95 midline, V 6.20 dura), ipsilateral to the 6-OHDA
lesion, and cemented in place with dental acrylic (Figure 4).
Artificial cerebrospinal fluid (CSF) (NaCl 125 mM, KC1 2.5 mM, NaH2P04 0.9
mM, Na2HP04 5 mM, MgCl2 1 mM, and CaCl2 1.2 mM in 100 ml deionized water) [24]
was perfused 2 (il/min through the microdialysis probe using a microperfusion pump
(Harvard Apparatus, PH2000, Holliston, MA). Accuracy of probe location was
histologically verified following cresyl violet staining of coronal cross-sections (40 (im)
of brain tissue (Figure 2).
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Figure 1. Timeline for the procedures performed.
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Figure 2. Verification of the microdialysis probe placement.
Placement of the microdialysis probe within the striatum was verified
histologically following cresyl violet staining of coronal cross-sections
(40 pm) of brain tissue. Arrow indicates the tip of the probe. Length of the
dialysis membrane is indicated by the area contained in the box.
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2.5. Stimulating Electrode Protocol
Shortly after the implantation of the microdialysis probe, a bipolar stainless steel
electrode (Plastics One, Roanoak, VA) was placed into the DRN (AP -11.5 bregma, Lat
0.0 midline, V 8.1 dura, angle 27°) and held there in place with the microdrive for the
remainder of the experimental protocol. The electrode was connected to a stimulator and
a constant current isolation unit (WPI, A365, Sarasota, FL). The DRN was stimulated
using a train of 1 ms, 300 pA, 5 Hz bipolar pulses [38] for 1 hour. The tip of the electrode
within the DRN was marked by making an electrolytic lesion (100 ms duration, 300 pA,
500 Hz unipolar pulses) at the termination of the experiment. Coronal cross-sections of
brain tissue (40 pm) were stained with cresyl violet (Figure 3) to localize the site.

2.6. Experimental Protocol
Following the microdialysis probe implantation, 2 hours were allowed for system
stabilization to occur [38]. Dialysates (100 pi) were then collected for 60 minutes to
determine basal striatal DA release (b_b). Over the next hour, the perfusate was collected
(100 pi) concurrent with DRN stimulation to determine stimulation-evoked DA release
(b_a).
Subsequently, the rats received an i.p. injection of Benserazide dissolved in 0.9%
NaCl with 0.1% ascorbate (50 mg/kg, Sigma, St. Louis, MO) (a peripheral amino acid
decarboxylase inhibitor) [31] followed 30 minutes later by application of the dopamine
precursor L-dopa dissolved in 0.1N HCL (200 mg/kg, i.p., Sigma, St. Louis, MO) [3].
Allowing 20 minutes for systemic absorption of the L-dopa, dialysates (100 pi) were then
collected for 60 minutes to measure basal DA release in the presence of exogenous L48

dopa (a_b)- Over the next hour, the perfusate was again collected with concurrent DRN
stimulation for determination of stimulated DA release with L-dopa present (a_a).
All samples were collected on ice and immediately stored at -80° C for later
detection of DA using high-performance liquid chromatography with electrochemical
detection (HPLC-EC).
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Figure 3. Verification of the stimulating electrode placement.
Location of the stimulating electrode was verified by creating an electrolytic
lesion at the termination of the experiment with subsequent coronal sections
(40 pm) stained with cresyl violet. Arrow indicates lesion site.
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Figure 4. Experimental setup.
A microdialysis probe was implanted and cemented in place within the striatum
ipsilateral to the DA lesion (AP +0.11 mm bregma, Lateral 2.95 mm midline,
Vertical 6.20 mm dura). A bipolar, stimulating electrode was also implanted in
the DRN (AP -11.5 mm bregma, Lateral 0.0 mm midline, Vertical 8.1 mm
dura, angle 27°).
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2.7. High-Performance Liquid Chromatography Protocol
The samples collected from the microdialysis probe are ultrafiltrates that can be
directly placed into an autoinjector and run through the HPLC column attached to a
coulometric electrochemical detector. Perchloric acid (0.1 M) was added to the samples
to prevent DA oxidation and DHBA was used as an internal standard. Individual
standards and a mixed standard were run at the beginning and end of a series. The
samples were run for 60 minutes at a high sensitivity (20 nA full scale), 175 mV, and
using 0.8 g octasulfonicacid (OSA)/500ml mobile phase. Identification of the unknown
peaks in sample chromatograms were determined by corresponding peaks identified from
individual standards. DA concentration was determined from the peak heights using the
calculations below.

(A) Raw Concentration

(B) Correction

= peak height (sample) X
peak height (standard)

concentration (standard)

peak height (internal standard)
peak height (external standard)

(C) Corrected Concentration = A X B

2.8. Physiological Monitoring During Surgery
The animals were monitored throughout the experiments to ensure proper
anesthesia (responsiveness to toe pinch) and acceptable physiological parameters
(respiratory rate, expired carbon dioxide levels, heart rate, hydration, and body
temperature). If dehydrated (determined by skin pinch test), 3 cc lactated ringer was
administered s.c. as needed.
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2.9. Statistical Analysis
DA release among the 6-OHDA-lesioned, 6-OHDA sham-lesioned, and control
rats were log transformed. The data did not meet the parametric assumptions of normality
and homogenity of variance determined using Levine’s test. Following log
transformation, both assumptions were met enabling the use of one-way analysis of
variance (ANOVA). Multiple comparisons were performed using the least significant
difference (LSD) post-hoc. The paired t-test was utilized to make paired comparison
within each group.
The non-parametric Kruskal-Wallis test was used to compare the difference in
DA release between the 6-OHDA + 5,7-DHT-lesioned, 6-OHDA + 5,7-DHT shamlesioned, and control animals since the Levine’s test indicated that the data did not meet
the assumptions of normality and homogeneity of variance. Log transformation of the
data did not satisfy the assumptions, requiring the use of the non-parametric KruskalWallis test with multiple comparisons [13]. The non-parametric Wilcoxon Signed Rank
test was utilized for paired comparisons within each group.
Analysis of DA release among 6-OHDA-lesioned compared to 6-OHDA + 5,7DHT-lesioned animals was made using the non-parametric Mann-Whitney U test. All
comparisons were considered to be significantly different if p < 0.05.
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3. Results
3.1. Comparison of DA Release Between 6-OHDA-Lesioned, 6-OHDA Sham-lesioned,
and Naive Control Animals
3. La. In the Absence of Exogenous L-dopa
Basal DA release was lower in the DA-depleted group compared to the shamlesioned and naive control animals (p = 0.062) (Figure 5) (b_b)- Post hoc analysis revealed
that DA release among the 6-OHDA-lesioned group was not significant (p = 0.091)
compared to sham-lesioned animals, however DA levels were significantly lower than the
control group (p = 0.025).
Stimulation-evoked DA release was also less in the 6-OHDA-lesioned as compared
to the sham-lesioned and control animals (p = 0.096) (b_a). Further analysis using a posthoc test revealed that basal release was not significantly different from the sham-lesioned,
but was significantly less than the control rats (p = 0.037). With DRN stimulation, DA
release was reduced relative to basal in the lesioned, sham-lesioned, and naive control
groups (p = 0.34, 0.068, and 0.027), respectively.

3.1.b. In the Presence of Exogenous L-dopa
L-dopa administration resulted in a significantly increased basal DA release in DAlesioned animals relative to sham-lesioned and naive control groups (p = 0.045) (Figure 5)
(a_b). Stimulation evoked DA release was further increased significantly in DA-depleted
animals relative to sham-lesioned and naive control rats (p = 0.03) (a_a).
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Figure 5. Comparison of basal and stimulation-evoked DA release in DA-lesioned (DA
Lesion), sham-lesioned (DA Sham), and naive control animals in the absence and
presence of exogenous L-dopa.
Each animal had a microdialysis probe and a stimulating electrode implanted into
the STR and DRN, respectively. Dialysates (100 jxl) were collected for 60
minutes during basal (b_b) and DRN electrical stimulation (b_a). Perfusates were
also collected under the same conditions subsequent to administered L-dopa, a_b
and a_a, respectively. In the absence of exogenous L-dopa, basal (p = 0.062)
(b_b) and stimulation-evoked (p = 0.096) (b_a) DA release was reduced in the
DA-depleted group compared to sham-lesioned and naive control animals.
Subsequent to L-dopa administration, basal DA release in DA-depleted animals
was significantly greater (p = 0.045) than sham-lesioned and naive control
groups (a_b)- Stmulation-evoked DA release remained significantly increased
(p = 0.03) subsequent to drug treatment in the lesioned animals with respect to
the nondenervated groups (a_a). Values represent the mean ± SEM and are
expressed as pg DA/pl). The data was log transformed and subsequently
analyzed using one way ANOVA. The LSD post-hoc was utilized to make
individual comparisons. P < 0.10 is indicated by # and P < 0.05 by *. N = 6-7.
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3.2. Comparison of DA Release Between 6-OHDA + 5,7-DHT-Lesioned, 6-OHDA-Sham
+ 5,7-DHT Sham-Lesioned, and Naive Control Animals
3.2. a. In the Absence of Exogenous L-dopa
6-OHDA + 5,7-DHT-lesioned animals showed significantly lower basal (p = 0.002)
(b_b) and stimulation-evoked (p = 0.004) (b_a) DA release relative to sham-lesioned and
control animals prior to L-dopa administration (Figure 6). Post-hoc analysis revealed that
the DA level in DA + 5-HT-lesioned animals was significantly lower without and during
stimulation compared to the sham-lesioned (p < 0.05) and the naive control groups
(p < 0.05). Paired comparisons of mean DA release before and during DRN stimulation
showed that DA concentration in all groups was reduced from basal (6-OHDA + 5,7-DHTlesioned, p = 0.27; sham-lesioned, p = 0.065; and control p = 0.027).

3.2.b. In the Presence of Exogenous L-dopa
Subsequent to exogenous L-dopa treatment, basal DA release (a_b) was
significantly reduced (p = 0.005) among DA + 5-HT-depleted when compared to shamlesioned and naive control groups (Figure 6). Post-hoc analysis revealed that basal DA
release was lower when the experimental rats were individually compared to the shamlesioned (p < 0.05) and naive control groups (p < 0.05).
Stimulation-evoked DA release (a_a) was also significantly reduced among DA +
5-HT-depleted (p = 0.033) relative to sham-lesioned and naive control animals. Individual
comparisons of DA release in 6-OHDA + 5,7-DHT-lesioned with sham-lesioned was
significantly lower (p < 0.05) as well as with naive control animals (p < 0.05).
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Figure 6. Comparison of basal and stimulation-evoked DA release in DA + 5-HT-lesioned
(DA + 5-HT), sham-lesioned (DA Sham + 5-HT Sham), and naive control
animals in the absence and presence of exogenous L-dopa.
Each animal had a microdialysis probe and a stimulating electrode implanted into
the STR and DRN, respectively. Dialysates (100 pi) were collected for 60
minutes during basal (b_b) and DRN electrical stimulation (b_a). Perfusates were
also collected under the same conditions subsequent to administered L-dopa, a_b
and a_a, respectively. Prior to L-dopa administration, DA + 5-HT-lesioned
animals showed significantly lower basal (p = 0.002) (b_b) and stimulationevoked (p = 0.004) (b_a) DA release relative to sham-lesioned and naive control
animals. Subsequent to exogenous L-dopa treatment, basal DA release was
significantly lower (p = 0.005) among DA + 5-HT-depleted compared to shamlesioned and naive control groups (a_b). With DRN stimulation, DA release
remained significantly reduced (p = 0.033) in experimental animals (a_a). Values
represent the mean ± SEM and expressed as pg DA/pl. The Kruskal-Wallis test
with multiple comparisons was utilized to analyze the data. P < 0.01 is indicated
by ** and P < 0.05 by*.N = 7.
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3.3. Effect of 5-HT Lesioning on Striatal DA Release
In the absence of exogenous L-dopa, both basal (b_b) and stimulation-evoked (b_a)
DA release did not differ between the 6-OHDA-lesioned and 6-OHDA + 5,7-DHTlesioned groups (Figure 7). However, basal DA release, subsequent to L-dopa treatment,
was significantly increased (p = 0.001) among DA-lesioned animals when compared to DA
+ 5-HT-depleted animals (a_b). Furthermore, DA release subsequent to exogenous L-dopa
and DRN stimulation resulted in a significant increase in DA levels measured among the
DA-depleted group relative to DA + 5-HT-lesioned animals (p = 0.008) (a_a).
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Figure 7. Effect of 5-HT lesioning on striatal DA release.
Effect of 5-HT lesioning was determined by comparing basal and stimulationevoked DA release in the absence and presence of L-dopa in DA-lesioned and
DA + 5-HT-lesioned animals. In the absence of exogenous L-dopa, both basal
(b_b) and stimulation-evoked (b_a) DA release did not differ between the DAlesioned and DA +5-HT-depleted animals. Subsequent to L-dopa treatment,
basal DA release was significantly increased (p = 0.001) in DA-depleted
relative to DA + 5-HT-lesioned (a_b)- With DRN stimulation, release was even
greater in DA-depleted animals (p = 0.008) (a_a). Values represent the mean ±
SEM and expressed as pg DA/pl. Mann-Whitney U Test was utilized to
analyze the data. P < 0.01 is indicated by **. N = 6 and 7.
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4. Discussion
This study suggests that following prolonged DA depletion, DA synthesis from
exogenous L-dopa occurs within striatal serotonergic neuron terminals that hyperinnervate
the DA-depleted STR. Prior to exogenous L-dopa administration, basal and stimulationevoked DA release was reduced in the DA-lesioned animals relative to the sham-lesioned
and naive control groups. The extracellular DA concentration during DRN stimulation
decreased relative to basal in all three groups which was expected because of the inhibitory
action of 5-HT neurons that innervate the SNc. Following exogenous L-dopa
administration, basal DA release was significantly increased in DA-denervated animals
relative to sham-lesioned and control groups. DA release remained significantly increased
during DRN stimulation in the presence of L-dopa. The increased DA release upon DRN
stimulation implicates serotonergic neurons are contributing to DA release from
administered L-dopa.
To investigate the contribution of 5-HT terminals, DA-denervated animals also
received a focal 5-HT lesion. Prior to L-dopa application, basal and stimulation-evoked
DA release did not differ between DA-lesioned and DA + 5-HT depleted animals.
However, during basal and stimulation-evoked DA release in the presence of exogenous
L-dopa was significantly lower than animals having only the DA lesion. DA release was
slightly increased in the presence of L-dopa during DRN stimulation, suggesting
incomplete 5-HT lesioning. Despite this, if a few 5-HT terminals remained, they were
unable to increase basal DA release. Comparison of DA release during all of the
conditions was significantly reduced in DA + 5-HT-depleted animals compared to shamlesioned and naive control groups. The 6-OHDA + 5,7-DHT sham-lesioned and naive

65

control animals also showed increased DA release subsequent to DRN stimulation. This
finding suggests that DRN serotonergic nerve terminals normally innervating the STR
contribute towards DA release from administered L-dopa. Overall, the results point
toward 5-HT neurons as being the primary source for DA release in the presence of
exogenous L-dopa.
The fact that some Parkinson’s patients are responsive to L-dopa for many years
despite progressive DA neuron degeneration supports the idea of alternative conversion
sites or “back-up” mechanisms. Serotonergic nerve terminals strongly qualify as the most
likely candidate for three reasons. First, they contain the enzyme necessary for DA
synthesis [5, 6, 28, 32, 46]. In fact, it has been shown that the AADC found in 5-HT and
DA neurons are equivalent [22, 28, 46]. Second, studies have demonstrated that
administered L-dopa can be taken up by 5-HT terminals, converted to DA, and released
[4, 32], Third, 5-HT terminals not only innervate the STR, but following severe DA
depletion they hyperinnervate the striatal areas where DA neurons previously resided [1,
14, 20, 37, 41, 45]. Thus, the increased number of 5-HT terminals provide potentially
greater sites whereby DA synthesis from exogenous L-dopa could occur. It should be
noted that 5-HT terminals are incapable of producing DA unless L-dopa has been
administered, as our results indirectly suggest.
As stated above, numerous investigators reported 5-HT hyperinnervation
subsequent to severe DA depletion. The concept of reinnervation within the DAdenervated striatum is logically conceivable since it is known that the brain is capable of
changing or adjusting in response to insult. Although striatal 5-HT hyperinnervation has
not been investigated in humans, to our knowledge, it is probable that some type of
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“new” innervation occurs. This can be supported by functional magnetic resonance
imaging of patients with PD [lacono, unpublished findings].
Although performed in rats, the results from our study provides insight into what
may be occurring in parkinsonian patients treated with L-dopa. These data demonstrate a
four-fold increase in basal DA release following L-dopa administration among DAdepleted animals when compared to the DA sham-lesioned and naive animals. DA
release was further increased with DRN stimulation within each group but remained
significantly greater in DA-depleted animals. All of the animals received the same dose
of the peripheral decarboxylase inhibitor, Benserazide, and L-dopa suggesting that
release among DA-lesioned animals was not regulated in the same manner as the control
groups (sham-lesioned and naive). Negative feedback systems exist in cells to regulate
the production and subsequent release of neurotransmitters to prevent too much from
entering the synaptic cleft. It is possible that the DA produced and released by 5-HT
terminals is not capable of regulating further DA release from these neurons.
Consequently, DA release is amplified. This may provide an explanation for the
occurrence of L-dopa-induced dyskinesias in PD patients treated with L-dopa.
Extracellular DA has three possible fates: metabolic breakdown by degradative
enzymes within the synaptic cleft, diffusion, or reuptake into serotonergic terminals by
the serotonin reuptake transporter (SERT). SERT has been shown to take up DA [9], but
with low affinity [16]. The increased extracellular DA concentration may overwhelm the
degradative enzymes and facilitate DA reuptake because of the increased concentration
gradient. Intraneuronal DA can be degraded by the enzyme monoamine oxidase A
(MAOa) or it can be vesicularized via active transport by the vesicular monoamine
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transporter (VMAT2) both of which minimize the amount of free DA within the neuron
terminal. However, possible competition with 5-HT may result in elevated intracellular
DA or 5-HT concentration which is cytotoxic to the terminals because of its ability to
oxidize spontaneously producing free radicals. Consequently, the 5-HT nerve terminals
would be subject to degeneration. This could help to explain why patients in the later
stages of PD appear to have 5-HT deficiencies (i.e, depression, dementia, anxiety, sleep
disturbances) [reviewed in 2, reviewed in 11,21]. This hypothesis, however, is purely
speculative requiring further experimentation to determine its validity.
In conclusion, the results from this study indirectly suggest that following
prolonged DA depletion, DA release from exogenous L-dopa primarily occurs from
serotonergic DRN neurons. These findings may have important implications toward
understanding L-dopa therapy in PD. For decades, how L-dopa can be therapeutically
effective among patients that are severely DA-depleted has been questioned. Since the
cause of the disease is not known, preventing further progression has not been
successfully attained. However, understanding the mechanisms of current therapeutic
regimens employed may lead to improved management of the disease.
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Abstract
Paradoxically, L-dopa ameliorates the symptoms of Parkinson’s disease, which is
characterized by severe, progressive dopamine (DA) neuron degeneration. With the loss
of uptake sites, DA synthesis from exogenous L-dopa warrants further investigation.
Remaining DA neurons, serotonergic dorsal raphe nucleus (DRN) neurons, and striatal
intemeurons are all potential sites for DA synthesis from administered L-dopa because of
the presence of amino acid decarboxylase (AADC) within their terminals.
Prior studies have shown striatal serotonergic hyperinnervation following severe
DA depletion. In addition, serotonin (5-HT) nerve terminals have been found to contain
DA subsequent to L-dopa administration. Thus, it is our hypothesis that the majority of
DA produced from exogenous L-dopa occurs within the 5-HT neurons that
hyperinnervate the DA-depleted striatum (STR). To support this, we have previously
demonstrated an increase in basal DA release following L-dopa treatment in rats with
prolonged DA depletion. The release was further increased with DRN stimulation.
Removal of 5-HT nerve terminals in DA-depleted animals eliminated the increase in
basal DA release subsequent to L-dopa administration. In this study, we tested the
hypothesis that in DA-depleted animals, striatal intemeurons are minor contributors
toward the conversion of exogenous L-dopa to DA by secondarily lesioning with
quinolinic acid (QA).
Sprague-Dawley rats were divided into 3 groups: 6-hydroxydopamine (6-OHDA)
+ QA-lesioned, 6-OHDA-sham + QA sham-lesioned, and naive controls. The 6-OHDA +
QA- lesioned and 6-OHDA-sham + QA sham-lesioned animals underwent pretreatment
with desipramine (10 mg/kg, i.p.) prior to receiving a unilateral injection of 6-OHDA (8
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fXg/4 |il ascorbic saline) or vehicle, respectively, within the medial forebrain bundle.
Severity of the lesion was determined by apomorphine testing 10 to 14 days post-surgery.
Eight to 16 months later, both groups of rats underwent a second surgery in which they
received an injection within the ipsilateral STR of QA (150 nmol) or vehicle,
respectively. The following week, all 3 groups of animals had a microdialysis probe
implanted into the ipsilateral STR and a stimulating electrode placed within the DRN.
DA concentration was measured at 4 time points: basal release, stimulation-evoked
release, basal release following L-dopa administration, and during DRN stimulation in
the presence of L-dopa.
In this study, we demonstrate that subsequent to L-dopa treatment, basal DA
release was significantly greater among the 6-OHDA + QA-lesioned animals when
compared to the sham-lesioned and naive control groups. DA release in the presence of
L-dopa was further increased upon DRN stimulation. There was no difference in basal or
stimulation-evoked DA release subsequent to L-dopa between the 6-OHDA + QAlesioned animals and those having only DA depletion from Chapter 2. On the other hand,
a significant increase in release was revealed under the same conditions when 6-OHDA +
QA-lesioned animals were compared to DA + 5-HT-depleted from Chapter 2. These
results indirectly suggest that striatal intemeurons are minor contributors to the
production of DA from exogenous L-dopa in animals with prolonged DA depletion.
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1. Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder
characterized by severe dopamine (DA) neuron depletion within the striatum (STR) and
the substantia nigra pars compacta (SNc). The most commonly prescribed medication
used to treat the DA deficiency is L-dopa, the DA precursor. Although the number of Ldopa uptake sites (presumably DA terminals) are severely diminished, patients
surprisingly respond to the drug regimen for a period of time. This has led investigators
to contemplate that conversion of exogenous L-dopa may not solely occur within
remaining DA terminals.
Several sites have been postulated to participate in DA synthesis from
administered L-dopa. Such sites include remaining DA terminals, serotonin (5-HT)
terminals, noradrenergic neurons, nonaminergic intemeurons, capillary endothelium, and
glial cells. All possible candidates contain the enzyme necessary to decarboxylate Ldopa, amino acid decarboxylase (AADC), and all innervate the STR. However, only the
dopaminergic terminals, serotonergic neurons, and striatal intemeurons are considered
viable [13, 14, 24-27,42, 44].
We demonstrated in Chapter 2 that DA release following exogenous L-dopa
administration occurs when the majority of DA neurons are lesioned. Stimulation of the
dorsal raphe nucleus (DRN) in the presence of L-dopa resulted in greater DA release
suggesting serotonergic nerve terminals as the most likely site of DA conversion.
Removal of the 5-HT-containing striatal terminals in DA-denervated animals eliminated
the significant increase in basal and stimulation-evoked DA release following L-dopa
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administration. The possible contribution of striatal intemeurons in exogenous L-dopaderived DA release remains to be addressed and is the focus of this study.
Striatal intemeurons also contain AADC providing another potential site for
production from exogenous L-dopa. It has been demonstrated that following intrastriatal
application of kainic acid (KA), an excitotoxin, AADC activity is reduced by
approximately 20% [14, 26]. KA is thought to be selectively toxic to cell bodies (i.e.,
striatal intemeurons and striatal efferent neurons) rather than presynaptic terminals or
fibers of passage [25]. If so, the reduction observed could be attributed to the
intemeurons rather than the result of damage to some of the DA terminals. Although
striatal intemeurons provide an alternative site for DA synthesis, it is questionable
whether these intemeurons can adequately compensate for the DA neuron loss in the
presence of exogenous L-dopa.
In this study, we investigated the role of striatal intemeurons in DA-depleted
animals by lesioning them with quinolinic acid (QA), an excitotoxin, in order to test the
hypothesis that they are insignificant contributors toward the conversion of exogenous Ldopa to DA. We demonstrate a significant increase in basal DA release following L-dopa
treatment among DA + QA-lesioned animals relative to sham-lesioned and naive control
groups. In the presence of L-dopa, stimulation-evoked DA release was also significantly
increased in experimental animals compared to both control groups. Comparison of
extracellular DA levels among DA-depleted animals with a striatal intemeuron lesion to
those having only a DA lesion (described in Chapter 2) show no significant difference
subsequent to L-dopa treatment. Although not statistically different, there was a trend of
less DA release with the intemeurons removed in DA-depleted animals. These results
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suggest that striatal intemeurons play a minor role in striatal utilization of exogenous Ldopa in the DA-depleted rat.

2. Materials and Methods
Eighteen, Sprague-Dawley rats (201- 275 g) (Harlan, San Diego, CA) were
divided into 3 different groups: 6-hydroxydopamine (6-OHDA) + QA-lesioned, 6OHDA-sham + QA sham-lesioned, and naive control. Individually caged animals were
housed in a temperature-controlled room with a 12-hour light-dark cycle with food and
water available ad libitum. Treatment of the rats was in full compliance under guidelines
established by the Loma Linda University Animal Care Committee and with the National
Medical Technology Test-bed.

2.7. Unilateral 6-Hydroxydopamine (6-OHDA) Lesion
An intraperitoneal (i.p.) injection of desipramine dissolved in deionized water (10
mg/kg, Sigma, St. Louis, MO) was administered to the experimental and sham-lesioned
animals (i.e., 6-OHDA + QA-lesioned and 6-OHDA-sham + QA sham-lesioned) forty
minutes prior to the first surgical procedure to prevent noradrenergic neurons from taking
up the 6-OHDA. Each rat was placed in a closed container under a fume hood with 1/2
ml isoflurane until anesthesia was attained (responsiveness to toe pinch). The animal was
rapidly placed into a stereotaxic frame and anesthesia maintained with isoflurane using a
pass-by system. An ophthalmic antibiotic ointment was applied to prevent corneal
desiccation during the procedure. Normal body temperature was maintained during
surgery using a heating pad and periodically checked with a rectal thermometer.
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Prior to making a midline incision on the scalp, 1/2 ml of bupivacaine HCL with
0.5% epinephrine was applied subcutaneously (s.c.) at the incision site. The skull was
exposed to locate lambda and bregma. The precise coordinates of the lesion site were
determined from the rat atlas of Paxinos and Watson [34],
The DA + QA-lesioned group (N = 6) received an injection of 6-OHDA (8 pg 6OHDA/4 pi ascorbic saline, 0.9% NaCl with 0.1% ascorbate, Sigma, St. Louis, MO) at a
rate of 0.2 pl/min [9, 13] within the left or the right medial forebrain bundle (MFB) (AP 4.4 bregma, Lat 1.0 midline, V 7.5 dura). Sham-lesioned animals (N = 6) received an
equivalent volume of ascorbic saline in the MFB. Control rats (N = 6) did not undergo
this surgical procedure. Three minutes after the completion of the neurotoxin infusion,
the needle was retracted (1 mm/min) and the scalp sutured with non-absorbable surgical
suture. Following surgery, the rats were returned to their cage, placed under a heat lamp,
and monitored frequently until they ambulated on their own.

2.2. Apomorphine Testing
Ten to 14 days following surgery, the rats (except the naive control group) were
administered an injection of apomorphine dissolved in saline (0.20 mg/kg, i.p., Sigma, St.
Louis, MO) [9] to assay the effectiveness of the DA lesioning (Figure 1). Only rats
having 6 or more rotations/min, contralateral to the side of the lesion, over a period of 15
minutes [9] were included in the experimental groups. The 6-OHDA sham-lesioned rats
failed to rotate.
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2.3. Apomorphine Re-Testing
To ensure that DA reinnervation did not occur, the 6-OHDA-lesioned and 6OHDA sham-lesioned were re-evaluated with apomorphine dissolved in saline (0.20
mg/kg, i.p., Sigma, St. Louis, MO) [9] 8 to 16 months following the 6-OHDA surgery.
Only rats having 6 or more rotations/min, contralateral to the side of the lesion, over a
period of 15 minutes [9] were included in the experimental groups (N = 6). All of the
animals tested fulfilled the qualification of the apomorphine challenge. The shamlesioned animals did not rotate to apomorphine (N = 6).

2.4. Unilateral Quinolinic Acid (QA) Lesion
One week following the second apomorphine testing, experimental animals
received 2 injections of a striatal intemeuron neurotoxin, QA. To ensure complete
depletion of the striatal intemeurons, QA (Sigma, St. Louis, MO) was injected into 2
different sites within the STR (AP +1.0 bregma, Lat 3.0 midline, V 5.2 dura and AP -0.4
bregma, Lat 3.05 midline, V 5.2 dura) ipsilateral to the 6-OHDA lesion. QA dissolved in
1 N NaOH with deionized water titrated to physiologic pH (7.4 - 7.6) (2 injections of 150
nmol/pl) [36] was injected at a rate of 0.2 pl/min. The QA sham-lesioned animals (N = 6)
received the vehicle equal in volume to that of the neurotoxin. Control animals (N = 6)
did not undergo this surgical procedure.

2.5. Apomorphine Re-Testing
One week following the QA or vehicle injection, the experimental and shamlesioned animals were re-tested using apomorphine (0.2 mg/kg, i.p., Sigma, St. Louis,
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MO) [35, 36] to assay the effectiveness of the QA lesioning. Only the rats having less
than 3 rotations/min, contralateral to the side of the lesion over a period of 15 minutes,
were included in the experimental group (N = 6). The 6-OHDA-sham + QA shamlesioned animals did not rotate (N = 6).
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Figure 1. Timeline for procedures performed.
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2.6. Microdialysis Protocol
Depending on the group, all of the rats underwent microdialysis at one of the
following time points: (1)1 week subsequent to the QA lesion or QA-sham surgery or (2)
24 to 36 weeks following their arrival (naive controls). The animals were prepared for
surgery in the same manner as that described for the 6-OHDA and 6-OHDA sham
surgical procedures.
A microdialysis probe was implanted into the STR (AP +0.11 bregma, Lat 2.95
midline, V 6.20 dura), ipsilateral to the 6-OHDA lesion, and cemented in place with
dental acrylic. Artificial cerebrospinal fluid (CSF) (NaCl 125 mM, KC1 2.5 mM,
NaH2P04 0.9 mM, Na2HP04 5 mM, MgC^ 1 mM, and CaCl2 1.2 mM in 100 ml
deionized water) [22] was perfused 2 pl/min through the microdialysis probe using a
microperfusion pump (Harvard Apparatus, PH2000, Holliston, MA). Probe location was
verified histologically following cresyl violet staining of coronal cross-sections (40 pm)
of brain tissue.

2.7. Stimulating Electrode Protocol
Following implantation of the microdialysis probe, a bipolar stainless steel
electrode (Plastics One, Roanoak, VA) was placed into the DRN (AP -11.5 bregma, Lat
0.0 midline, V 8.1 dura, angle 27°) and held in place with the microdrive for the
remainder of the experimental protocol. The electrode was connected to a stimulator and
a constant current isolation unit (WPI, A365, Sarasota, FL). The DRN was stimulated
using a train of 1 ms duration, 300 pA, 5 Hz bipolar pulses [39] for 1 hour. The tip of the
electrode within the DRN was marked by making an electrolytic lesion (100 ms duration,
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300 jjA, 500 Hz unipolar pulses) at the termination of the experiment. Coronal crosssections of brain tissue (40 jxm) were stained with cresyl violet to localize the site.

2.8. Experimental Protocol
Following the microdialysis probe implantation, 2 hours were allowed for system
stabilization to occur [39]. Dialysates (100 pi) were then collected for 60 minutes to
determine basal striatal DA release (b_b). Over the next hour, the perfusate was collected
(100 pi) concurrent with DRN stimulation to determine stimulation-evoked DA release
(b_a).
Subsequently, the rats received an i.p. injection of Benserazide dissolved in 0.9%
NaCl with 0.1% ascorbate (50 mg/kg, Sigma, St. Louis, MO) (a peripheral amino acid
decarboxylase inhibitor) [30] followed 30 minutes later by application of the DA
precursor L-dopa dissolved in 0.1 N HCL (200 mg/kg, i.p., Sigma, St. Louis, MO) [3].
Allowing 20 minutes for systemic absorption of the L-dopa, dialysates (100 pi) were then
collected for 60 minutes to measure basal DA release in the presence of exogenous Ldopa (a_b). Over the next hour, the perfusate was again collected with concurrent DRN
stimulation for determination of stimulated DA release with L-dopa present (a_a).
All samples were collected on ice with simultaneous infusion of 0.1 M perchloric
acid (PCA) to prevent degradation of DA. They were then immediately stored at -80° C
for later detection of dopamine using high-performance liquid chromatography with
electrochemical detection (HPLC-EC).
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2.9. High Performance Liquid Chromatography
The samples collected from the microdialysis probe are ultrafiltrates that can be
directly placed into an autoinjector and run through the HPLC column attached to a
coulometric electrochemical detector. Perchloric acid (0.1 M) was added to the samples
to prevent DA oxidation and DHBA as an internal standard. Individual standards and a
mixed standard were run at the beginning and end of a series. The samples were run for
60 minutes at a high sensitivity (20 nA full scale), 175 mV, and using 0.8 g
octasulfonicacid (OSA)/500ml mobile phase. Identification of the unknown peaks in
sample chromatograms were determined by corresponding peaks identified from
individual standards. DA concentration was determined from the peak heights using the
calculations below.

(A) Raw Concentration

(B) Correction

= peak height (sample) X
peak height (standard)

concentration (standard)

peak height (internal standard)
peak height (external standard)

(C) Corrected Concentration = A X B

2.10. Physiological Monitoring During Surgery
The animals were monitored throughout the experiments to ensure proper
anesthesia (responsiveness to toe pinch) and acceptable physiological parameters
(respiratory rate, expired carbon dioxide levels, heart rate, hydration, and body
temperature). If dehydrated (determined by skin pinch test), 3 cc lactated ringer was
administered s.c. as needed.
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2.11. Statistical Analysis
The non-parametric Kmskal-Wallis test was used to compare the difference in
DA release between the 6-OHDA + QA-lesioned, 6-OHDA-sham + QA sham-lesioned,
and naive control animals. The data did not meet the parametric assumptions of normality
and homogeneity of variance. Log transformation did not correct the problem requiring
the use of the non-parametric Kruskal-Wallis test with multiple comparisons [12]. The
non-parametric Wilcoxon Signed Rank test was utilized for paired comparisons within
each group.
Analysis of DA release in the 6-OHDA + QA-lesioned compared to animals
having only the 6-OHDA lesion was made using the non-parametric Mann-Whitney U
test. This statistical test was also utilized for comparing 6-OHDA + QA-lesioned with 6OHDA + 5,7-DHT-lesioned groups. All comparisons were considered to be significantly
different if p < 0.05.

3.

Results

3.1 Comparison of DA Release Between 6-OHDA + QA-Lesioned, 6-OHDA-sham + QA
Sham-Lesioned, and Naive Control Animals
3.1. a. In the Absence of Exogenous L-dopa
Basal DA release was significantly reduced (p = 0.023) among the DA + QAlesioned when compared to the sham-lesioned and control groups (Figure 2) (b_b). Post
hoc analysis revealed that the DA level in the DA + QA-lesioned animals was
significantly less than (p < 0.05) the naive controls, but not the sham-lesioned animals
(p > 0.05).
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On the other hand, during DRN stimulation, DA concentration did not differ
between the three groups (p = 0.365) (b_a). A decrease in DA release occurred when
paired comparisons, before and during stimulation, within each group were performed
(DA + QA-lesioned, p = 0.116; DA-sham + QA sham-lesioned, p = 0.173; controls,
p = 0.027).

3. Lb. In the Presence of Exogenous L-dopa
Basal DA release was significantly greater (p = 0.004) in the DA + QA-lesioned
compared to the sham-lesioned and control animals (Figure 2) (a_b)- Further analysis
using a post-hoc test revealed that basal DA release was also greater when the
experimental rats were individually compared to the sham-lesioned (p < 0.05) and naive
control groups (p < 0.05).
Likewise, stimulation-evoked DA release, in the presence of administered L-dopa,
was significantly increased (p = 0.001) among the DA + QA-lesioned animals relative to
the sham-lesioned and naive control animals (a_a). A significant increase in DA
concentration was also revealed with post hoc analysis among DA + QA-lesioned
animals with sham-lesioned (p < 0.05) as well as with naive control groups (p < 0.05).

3.2. Effect of Striatal Intemeuron Lesioning on Striatal DA Release
DA-depleted animals described in Chapter 2 were compared to DA-lesioned
animals also having a striatal intemeuron lesion. In the absence of exogenous L-dopa,
both basal (p = 0.937) (b_b) and stimulation-evoked (p = 0.699) (b_a) DA release did not
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differ between the DA + QA-lesioned and animals having only the DA lesion (Figure 3).
Basal DA release subsequent to L-dopa treatment also did not differ statistically
(p = 0.818) among DA + QA-lesioned when compared to DA-denervated animals (a_b)Similarly, there was not a significant difference in stimulation-evoked DA release
following exogenous L-dopa between the two groups (p = 0.394) (a_a).

3.3. Comparison Between the Effect of Striatal Intemeuron Lesioning and Serotonin
Depletion on Striatal Dopamine Release
Animals receiving both a DA lesion within the MFB and a 5-HT lesion within the
STR described in Chapter 2 were compared to DA-depleted animals also having a striatal
intemeuron lesion. Prior to L-dopa administration, basal DA release did not differ
statistically (p = 0.138) between the DA + QA-lesioned animals and DA + 5-HTdenervated group (Figure 4) (b_b). However, during DRN stimulation a significant
difference (p = 0.014) in DA release resulted between the two groups (b_a). Subsequent
to exogenous L-dopa application, basal (p = 0.001) (a_b) and stimulation-evoked
(p = 0.001) (a_a) DA release was significantly increased in the DA + QA-lesioned
animals when compared to the DA + 5-HT-lesioned group.
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Figure 2. Comparison of basal and stimulation-evoked DA release in DA + QA-lesioned
(DA + QA Lesion), sham-lesioned (DA Sham + QA Sham), and naive control
animals in the absence and presence of exogenous L-dopa.
Each animal had a microdialysis probe and a stimulating electrode implanted
into the STR and DRN, respectively. Dialysates (100 pi) were collected for
60 minutes during basal (b_b) and DRN electrical stimulation (b_a). Perfusates
were also collected under the same conditions subsequent to administered Ldopa, a_b and a_a, respectively. In the absence of exogenous L-dopa, basal
(b_b) (p = 0.023) and stimulation-evoked (b_a) (p = 0.365) DA release was
reduced in the DA + QA-lesioned group compared to sham-lesioned and
control animals. Subsequent to L-dopa administration, basal DA release in DA
+ QA-lesioned animals was significantly greater (p = 0.004) than shamlesioned and control groups (a_b). Stimulation-evoked DA release remained
significantly increased in the experimental animals relative to both control
groups subsequent to drug treatment (a_a) (p = 0.001). Values represent the
mean ± SEM and expressed as pg DA/pl. The Kruskal-Wallis test with
multiple comparisons was utilized to analyze the data. P < 0.01 is indicated by
and P < 0.05 by *. N = 6.
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Figure 3. Effect of striatal intemeuron lesioning on striatal DA release.
Effect of striatal intemeuron lesioning was determined by comparing basal and
stimulation-evoked DA release in the absence and presence of L-dopa in DAdepleted and DA + QA-lesioned animals. In the absence of exogenous L-dopa,
both basal (b_b) (p = 0.937) and stimulation-evoked (b_a) (p = 0.699) DA
release did not differ between the DA-depleted and DA + QA-lesioned animals.
Likewise, subsequent to L-dopa treatment, basal DA release was not
significantly different (p = 0.818) in DA-depleted from DA + QA-lesioned
animals (a_b)- With DRN stimulation, although release increased in both
groups, it was not significantly different (a_a) (p = 0.394). Values represent the
mean ± SEM and expressed as pg DA/pl Mann-Whitney U Test was utilized
to analyze the data. N = 6.
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Figure 4. Comparison Between the Effect of Striatal Intemeuron Lesioning and
Serotonin Depletion on Striatal Dopamine Release.
Effect of 5-HT lesioning was determined by comparing basal and
stimulation-evoked DA release in the absence and presence of L-dopa in DA +
QA-lesioned and DA + 5-HT-depleted animals. In the absence of exogenous Ldopa, basal (b_b) (p = 0.138) DA release do not differ between the DA +QAlesioned and DA +5-HT-depleted animals. Although release decreased with
DRN stimulation in both groups, the DA level was greater among the DA +
QA-lesioned animals (b_a) (p = 0.014). Subsequent to L-dopa treatment, basal
DA release was significantly increased (p = 0.001) in DA + QA-lesioned
relative to DA + 5-HT-depleted (a_b)- With DRN stimulation in the presence of
L-dopa, release was even greater in DA + QA-lesioned animals (p = 0.001)
(a_a). Values represent the mean ± SEM and expressed as pg DA/pl. MannWhitney U Test was utilized to analyze the data. P < 0.01 is indicated by **
and P < 0.05 by *. N = 6 and 7.
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4. Discussion
This study shows that following prolonged DA depletion, DA synthesis from
exogenous L-dopa occurs in the absence of striatal intemeurons. In 6-OHDA + QAtreated animals, exogenous L-dopa administration resulted in a significant increase in
basal DA release relative to sham-lesioned and naive control animals. DA release
increased with DRN stimulation in all groups but remained significantly greater in the 6OHDA + QA-lesioned animals when compared to both control groups (sham-lesioned
and naive). Results from apomorphine re-testing 8 to 16 months post-6-OHDA lesion
show that a large increase in DA release from reinnervated striatal DA terminals is
unlikely.
Although DA conversion from exogenous L-dopa occurs when striatal
intemeurons are absent, they may participate to some degree in DA synthesis and release.
To assess their contribution, DA release among DA + QA-lesioned animals was
compared to animals having only a DA lesion from Chapter 2. There was no significant
difference under any of the experimental conditions between these groups. However, in
the presence of L-dopa, basal and stimulation-evoked DA release was reduced 35% and
21% among the DA + QA-lesioned animals compared to the DA-depleted group,
respectively. These results suggest that striatal intemeurons contribute to some of the DA
released from exogenous L-dopa.
Interestingly, DA release subsequent to L-dopa treatment increased during DRN
stimulation in all of the groups (6-OHDA + QA-treated, 6-OHDA-sham + QA shamlesioned, and naive controls) with the most significant increase among the 6-OHDA +
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QA-treated animals. These results suggest that 5-HT neurons originating from the DRN
may be important in DA synthesis among animals with prolonged DA depletion.
To further investigate this, 6-OHDA + QA-lesioned animals were compared to
DA-depleted animals also having a 5-HT lesion from Chapter 2. In the presence of Ldopa, DA release was 97% and 88% greater among 6-OHDA + QA-lesioned animals
during basal and DRN stimulation, respectively. These results provide support for
serotonergic neurons as a primary site of DA synthesis from exogenous L-dopa.
We previously reported a large increase in basal DA release in DA-depleted
animals treated with L-dopa. Stimulation of serotonergic terminals originating from the
DRN resulted in greater DA release in the presence of L-dopa indirectly suggesting 5-HT
terminals as a possible site of conversion. Removal of 5-HT terminals in DA-denervated
animals eliminated the increased DA release in the basal and stimulation-evoked
conditions subsequent to L-dopa administration. The question remained as to the possible
contribution of striatal intemeurons as a site of L-dopa conversion. The participation of
striatal intemeurons was indirectly answered by striatal lesioning with QA in DAdepleted animals. The data from this study demonstrate an eight-fold and a four-fold
increase in basal DA release following L-dopa administration among 6-OHDA + QAlesioned animals when compared to sham-lesioned and naive controls, respectively.
However, basal DA release among DA + QA-lesioned animals was 35% less than DAdepleted animals from Chapter 2 in the presence of L-dopa. In conclusion, our results
show that striatal intemeurons play a minor role in striatal utilization of exogenous Ldopa in DA-depleted rats.
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NOTE: This study was sponsored by the Department of the Army (cooperative agreement
number DAMD17-97-2-7016). The content of the information does not necessarily reflect
the position or the policy of the government or NMTB, and no official endorsement should
be inferred.
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Abstract
Although Parkinson’s disease results from a severe deficiency within the
nigrostriatal dopaminergic system, patients are commonly diagnosed with depression and
other disorders related to serotonin (5-HT) loss in later stages of the disease. Consequently,
selective serotonin reuptake inhibitors (SSRIs) are generally administered to replenish the
transmitter deficit. Numerous studies have documented striatal serotonergic
hyperinnervation subsequent to severe dopamine (DA) depletion. In addition, these
serotonergic terminals have been shown to participate in DA synthesis from exogenous Ldopa. The use of striatal serotonergic neurons in the conversion of administered L-dopa to
DA may help to explain the 5-HT deficiency in many PD patients.
Sprague-Dawley rats were divided into 3 groups: DA-lesioned, DA sham-lesioned,
and naive controls. All animals (except for controls) were administered desipramine
(lOmg/kg, i.p.) prior to a unilateral injection of 6-hydroxydopamine (6-OHDA, 8pg/4 pi
ascorbic saline) or vehicle within the medial forebrain bundle (MFB) of DA-lesioned and
sham-lesioned, respectively. After waiting 6 to 18 months for hyperinnervation by
serotonergic neurons in the DA-denervated striatum (STR), all animals underwent
implantation of a microdialysis probe within the ipsilateral STR and a bipolar stimulating
electrode in the dorsal raphe nucleus (DRN). Samples were collected to determine DA
concentration under four conditions: basal release, during DRN stimulation, basal release
subsequent to Celexa (a SSRI) and L-dopa administration, and concurrent with DRN
stimulation in the presence of Celexa and L-dopa. DA concentration was determined by
high-performance liquid chromatography with electrochemical detection.
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This study was able to demonstrate that basal DA release did not differ between the
DA-lesioned, DA sham-lesioned, and naive control groups subsequent to Celexa and Ldopa administration. On the other hand, following L-dopa application, there was a four-fold
decrease in basal DA release in DA-lesioned animals treated with the SSRI relative to DAdepleted animals from Chapter 2. Lesioning striatal 5-HT terminals in DA-depleted
animals from Chapter 2 eliminated the increase in basal DA release. The finding of
decreased striatal DA release in the presence of Celexa provide another line of evidence
implicating serotonergic nerve terminals in DA synthesis from exogenous L-dopa in DAdepleted rats.
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1. Introduction
Approximately 40 to 60% of patients with Parkinson’s disease (PD) are clinically
depressed [reviewed in 2]. The percentage increases to 80% with increasing age and
disease progression [reviewed in 12]. Selective serotonin reuptake inhibitors (SSRIs) are
commonly utilized to treat the serotonin (5-HT) deficiency. However, some criticize the
use of SSRIs claiming that they induce extrapyramidal reactions (EPRs) [9] and cause
further deterioration of motor function [38].
SSRIs act to inhibit the serotonin reuptake tranporter (SERT) located on 5-HT
presynaptic nerve terminals. The SERT transporter functions to remove 5-HT from the
synaptic cleft and subsequently modulate further 5-HT release. Under normal conditions,
SSRIs potentiate serotonergic activity by blocking 5-HT clearance from the synaptic cleft
by SERT allowing for greater extracellular 5-HT concentrations.
The most effective and potent drug in the treatment of PD is L-dopa, the precursor
of dopamine (DA). Although L-dopa does not slow the disease progression, it does act to
reverse the symptoms for a period of time by addressing the DA deficiency. However,
despite its potency, response to L-dopa declines as the disease progresses. It is questionable
whether the treatment becomes ineffective as a result of the inherent nature of the disease
process or the toxicity of L-dopa.
It is not understood where L-dopa conversion to DA occurs in PD. As
discussed in the prior chapters, remaining dopaminergic terminals, dorsal raphe nucleus
(DRN) serotonergic terminals, and striatal intemeurons are the only viable sites.
Undoubtedly the conversion occurs within the remaining DA terminals. But as the disease
proceeds, there is further DA neuron degeneration resulting in fewer sites for DA synthesis
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from administered L-dopa. The occurrence of serotonergic hyperinnervation and the
capability of 5-HT neurons to contain DA following L-dopa administration suggests
serotonergic nerve terminals as the most likely site of DA conversion.
We previously demonstrated an increase in DA release subsequent to L-dopa
treatment among animals with prolonged DA depletion in Chapter 2. Release was further
increased with dorsal raphe nucleus (DRN) stimulation providing support for DA
conversion within 5-HT terminals. Depletion of striatal serotonergic terminals in DAdepleted animals eliminated the increase in DA release (both basal and stimulation-evoked
release) following L-dopa administration providing further support for serotonergic neuron
participation in DA conversion. Removal of striatal intemeurons in DA-depleted animals
indicated in Chapter 3 that they are minor contributors to exogenous L-dopa-derived DA.
This study was performed to further investigate the role of serotonergic terminals in
DA release following L-dopa administration. It is our hypothesis that Celexa (a SSRI)
administration will reduce exogenous L-dopa-derived DA release from 5-HT striatal
terminals in the DA-depleted rat. In this study we demonstrate following L-dopa
application, there is no difference in basal DA release among DA-depleted animals treated
with Celexa relative to sham-lesioned and naive control groups. Further, in the presence of
L-dopa, comparison of extracellular DA concentration among DA-denervated animals
administered Celexa were lower than DA-depleted animals from Chapter 2 and higher than
animals having both a DA and 5-HT lesion from Chapter 2. These results suggest that
Celexa reduces uptake of exogenously administered L-dopa and subsequently reduces DA
released from sertonergic nerve terminals in the striatum.
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2. Materials and Methods
Eighteen male, Sprague-Dawley rats (201 - 297 g) (Harlan, San Diego, CA) were
divided into 3 different groups: 6-OHDA-lesioned, 6-OHDA sham-lesioned, and naive
control. Individually caged animals were housed in a temperature-controlled room with a
12-hour light-dark cycle with food and water available ad libitum. Treatment of the rats
was in accordance with the Animal Care Committee of Loma Linda University and the
National Medical Technology Test-bed.

2.7. Unilateral 6-Hydroxydopamine (6-OHDA) Lesion
The experimental and sham-lesioned groups were administered an intraperitoneal
(i.p.) injection of desipramine dissolved in deionized water (10 mg/kg, Sigma, St. Louis,
MO) forty minutes prior to the first surgical procedure to minimize the ability of
noradrenergic neurons from taking up the 6-OHDA. Each rat was placed in a closed
container under a fume hood with 1/2 ml isoflurane until anesthesia was attained (i.e., not
responsive to toe pinch). The animal was rapidly placed into a stereotaxic frame and
anesthesia was maintained with isoflurane using a pass-by system. An ophthalmic
antibiotic ointment was applied to prevent corneal desiccation during the procedure.
Normal body temperature was maintained during surgery using a heating pad and
periodically checked with a rectal thermometer.
Local anesthesia, bupivacaine HCL with 0.5 % epinephrine (1/2 ml), was applied
subcutaneously (s.c.) at the incision site prior to making a midline incision on the scalp.
The skull was exposed to locate lambda and bregma. The precise coordinates of the
lesion site were determined from the rat atlas of Paxinos and Watson [34].
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The experimental group (N = 6) received an injection of 6-OHDA (8 pg 6-OHDA/4
pi ascorbic saline, 0.9 % NaCl with 0.1% ascorbate, Sigma, St. Louis, MO) at a rate of 0.2
pl/min [10, 16] within the left or the right medial forebrain bundle (MFB) (AP -4.4
bregma, Lat 1.0 midline, V 7.5 dura). Sham-lesioned rats (N = 6) received an equal volume
of ascorbic saline in the MFB. Naive control rats (N = 6), did not undergo this surgical
procedure. Three minutes after the completion of the neurotoxin infusion, the needle was
retracted (1 mm/min) and the scalp sutured. Following surgery, the rats were returned to
their cages, placed under a heat lamp, and monitored frequently until they ambulated on
their own.

2.2. Apomorphine Testing
Ten to 14 days following surgery, the rats (except the naive control group) were
administered an injection of apomorphine dissolved in saline (0.20 mg/kg, i.p., Sigma, St.
Louis, MO) [10] to assay the effectiveness of the DA lesioning (Figure 1). Only rats having
6 or more rotations/min, contralateral to the side of the lesion, over a period of 15 minutes
[10] were included in the experimental group.

2.3. Microdialysis Protocol
According to the respective group, all of the rats underwent microdialysis at one
the following time points: (1) 7 to 11 months following the 6-OHDA (N = 6) or 6-OHDA
sham (N = 6) lesion or (2) 6 to 18 weeks following their arrival (naive control group) (N
= 6). The animals were prepared for surgery in the same manner as that described for the
6-OHDA and 6-OHDA-sham surgical procedures. A microdialysis probe was implanted
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into the STR (AP +0.11 bregma, Lat 2.95 midline, V 6.20 dura), ipsilateral to the 6OHDA lesion, and cemented in place with dental acrylic.
Artificial cerebrospinal fluid (CSF) (NaCl 125 mM, KC1 2.5 mM, Nat^PCU 0.9
mM, Na2HP04 5 mM, MgCl21 mM, and CaC^ 1.2 mM in 100 ml deionized water) [26]
was perfused 2 pl/min through the microdialysis probe using a microperfusion pump
(Harvard Apparatus, PH2000, Holliston, MA). Localization of the probe was verified
histologically following cresyl violet staining of coronal cross-sections (40 pm) of brain
tissue.

Ill

Figure 1. Timeline for the procedures performed.
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2.4. Stimulating Electrode Protocol
Shortly after the implantation of the microdialysis probe, a bipolar stainless steel
electrode (Plastics One, Roanoak, VA) was placed into the DRN (AP -11.5 bregma, Lat
0.0 midline, V 8.1 dura, angle 27°) and held there in place with the microdrive for the
remainder of the experimental protocol. The electrode was connected to a stimulator and
a constant current isolation unit (WPI, A365, Sarasota, FL). The DRN was stimulated
using a train of 1 ms, 300 pA, 5 Hz bipolar pulses [37] for 1 hour. The tip of the electrode
within the DRN was marked by making an electrolytic lesion (100 ms duration, 300 pA,
500 Hz unipolar pulses) at the termination of the experiment. Coronal cross-sections of
brain tissue (40 pm) were stained with cresyl violet to localize the site.

2.5. Experimental Protocol
Following the microdialysis probe implantation, 2 hours were allowed for system
stabilization to occur [37]. Dialysates (100 pi) were then collected for 60 minutes to
determine basal striatal DA release (b_b)- Over the next hour, the perfusate was collected
(100 pi) concurrent with DRN stimulation to determine stimulation-evoked DA release
(b_a).
Subsequently, the rats received an i.p. injection of Celexa (20 mg/kg, Forest
Pharmaceuticals, St. Louis, MO) (a selective serotonin reuptake inhibitor) 30 minutes prior
to Benserazide dissolved in 0.9% NaCl with 0.1% ascorbate (50 mg/kg, Sigma, St. Louis,
MO) (a peripheral amino acid decarboxylase inhibitor) [32]. L-dopa dissolved in 0.1N
HCL (200 mg/kg, i.p., Sigma, St. Louis, MO), the precursor of DA, was administered 30
minutes later [3]. Allowing 20 minutes for systemic absorption of the L-dopa, dialysates
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(100 |il) were then collected for 60 minutes to measure basal DA release in the presence of
exogenous L-dopa (a_b)- Over the next hour, the perfusate was again collected with
concurrent DRN stimulation for determination of stimulated DA release with L-dopa
present (a_a).
All samples were collected on ice and immediately stored at -80° C for later
detection of DA using high-performance liquid chromatography with electrochemical
detection (HPLC-EC).

2.6. High-Performance Liquid Chromatography Protocol
The samples collected from the microdialysis probe are ultrafiltrates that can be
directly placed into an autoinjector and run through the HPLC column attached to a
coulometric electrochemical detector. Perchloric acid (0.1 M) was added to the samples
to prevent DA oxidation and DHBA was used as an internal standard. Individual
standards and a mixed standard were run at the beginning and end of a series. The
samples were run for 60 minutes at a high sensitivity (20 nA full scale), 175 mV, and
using 0.8 g octasulfonicacid (OSA)/500ml mobile phase. Identification of the unknown
peaks in sample chromatograms were determined by corresponding peaks identified from
individual standards. DA concentration was determined from the peak heights using the
calculations below.

(A) Raw Concentration

(B) Correction

peak height (sample) X concentration (standard)
peak height (standard)

peak height (internal standard)
peak height (external standard)

(C) Corrected Concentration = AXB

115

2.7. Physiological Monitoring During Surgery
The animals were monitored throughout the experiments to ensure proper
anesthesia (responsiveness to toe pinch) and acceptable physiological parameters
(respiratory rate, expired carbon dioxide levels, heart rate, hydration, and body
temperature). If dehydrated (determined by skin pinch test), 3 cc lactated ringer was
administered s.c. as needed.

2.8. Statistical Analysis
The non-parametric Kruskal-Wallis test was used to compare the difference in
DA release between the 6-OHDA-lesioned, 6-OHDA sham-lesioned, and control
animals. The data did not meet the parametric assumptions of normality and homogeneity
of variance. Log-transformation did not correct the problem requiring the use of a nonparametric Kruskal-Wallis test with multiple comparisons [14]. The non-parametric
Wilcoxon Signed Rank Test was utilized for paired comparisons within each group.
Individual analyses of DA release among DA-lesioned animals treated with
Celexa compared to DA-lesioned (from Chapter 2), DA + 5-HT-lesioned (from Chapter
2), or 6-OHDA + quinolinic acid (QA)-lesioned (from Chapter 3) were made using the
non-parametric Mann-Whitney U test. All comparisons were considered to be
significantly different if p <0.05.
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3. Results
3.1 Comparison of DA Release Between 6-OHDA-Lesioned, 6-OHDA Sham-Lesioned, and
Naive Control Animals Treated With Celexa
3.1. a. In the Absence of Exogenous L-dopa
Basal DA release was significantly reduced among the DA-lesioned compared to
the sham-lesioned and control groups (p = 0.007) (Figure 2) (b_b)- Post hoc analysis
revealed that the extracellular DA level in the DA-depleted animals was significantly lower
(p < 0.05) than the naive controls and the sham-lesioned animals (p < 0.05).
Likewise, during DRN stimulation, DA concentration was significantly lower in
DA-depleted animals relative to sham-lesioned and control groups (p = 0.007) (b_a).
Further analysis using a post-hoc showed that stimulation-evoked DA release in the DAlesioned group was significantly reduced compared to sham-lesioned (p < 0.05) and control
animals (p < 0.05).

3.1.b. In the Presence of Exogenous L-dopa
Subsequent to L-dopa administration, basal DA release did not differ significantly
between the three groups (p = 0.459) (Figure 2) (a_b)- Post-hoc analysis did not reveal any
statistical difference in DA concentration.
On the other hand, during DRN stimulation in the presence of L-dopa, DA
concentration increased significantly in the DA-lesioned animals compared to shamlesioned and control groups (p = 0.006) (a_a). A significant increase in DA was revealed
with post hoc analysis among DA-depleted with sham-lesioned (p < 0.05) as well as with
naive control animals (p < 0.05).
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Figure 2. Effect of Celexa on basal and stimulation-evoked DA release in DAlesioned (DA Lesion), DA sham-lesioned (DA Sham), and naive control animals
in the absence and presence of exogenous L-dopa.
Each animal had a microdialysis probe and a stimulating electrode implanted into
the STR and DRN, respectively. Dialysates (100 pi) were collected for 60
minutes during basal (b_b) and DRN electrical stimulation (b_a). Perfusates were
also collected under the same conditions following Celexa and L-dopa
application, a_b and a_a, respectively. In the absence of exogenous L-dopa, basal
(p = 0.007) (b_b) and stimulation-evoked (p = 0.007) (b_a) DA release was
reduced in the DA-depleted group compared to sham-lesioned and naive control
groups. Subsequent to Celexa and L-dopa administration, basal DA release did
not differ between the three groups (p = 0.459). However, stimulation-evoked
DA release was significantly increased in DA-lesioned animals relative to shamlesioned and control groups subsequent to drug treatment (Celexa and L-dopa) (p
= 0.006) (a_a). Values represent the mean ± SEM and are expressed as pg
DA/pl. Kruskal-Wallis test with multiple comparisons was utilized to analyze
the data. P < 0.01 is indicated by **. N = 6 in each group.
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3.2. Effect of Serotonin Reuptake Inhibition on Striatal Dopamine Release
DA-depleted animals described in Chapter 2 were compared to DA-lesioned
animals treated with Celexa. In the absence of exogenous L-dopa, both basal (p = 0.937)
(b_b) and stimulation-evoked (p = 0.589) (b_a) DA release did not differ between the DAlesioned animals treated with Celexa (DA + Celexa) and DA-depleted animals not
administered the SSRI (Figure 3). Subsequent to L-dopa treatment, there was a four-fold
decrease in basal DA release, although not significant, in DA-depleted animals treated with
Celexa and DA-denervated animals (p = 0.240) (a_b)- In the presence of L-dopa,
stimulation-evoked DA release increased in both groups but remained lower in the DA +
Celexa animals relative to DA-lesioned animals not treated with Celexa (p = 0.132) (a_a).

3.3. Comparison Between the Effects of Serotonin Depletion and Serotonin Reuptake
Inhibition on Striatal Dopamine Release
Animals receiving a DA lesion within the STR described in Chapter 2 were
compared to DA-denervated animals treated with Celexa. Prior to L-dopa administration,
basal DA release did not differ statistically between the DA-lesioned animals treated with
Celexa and DA + 5-HT-lesioned animals (p = 0.138) (Figure 4) (b_b)- However, during
DRN stimulation in the absence of L-dopa, DA release was significantly greater in the DA
+ Celexa group compared to the DA + 5-HT-depleted (p = 0.014) (b_a). Subsequent to
exogenous L-dopa application, basal (p = 0.001) (a_b) and stimulation-evoked (p = 0.035)
(a_a) DA release was significantly increased in the DA + Celexa animals when compared
to the DA + 5-HT-depleted group.
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Figure 3. Effect of Serotonin Reuptake Inhibition on Striatal Dopamine Release.
Comparison of basal and stimulation-evoked DA release in the presence and
absence of L-dopa in DA-lesioned and DA-lesioned animals treated with
Celexa. In the absence of exogenous L-dopa, both basal (p = 0.937) (b_b) and
stimulation-evoked (p = 0.589) (b_a) DA release did not differ between the
groups. Subsequent to L-dopa treatment, basal DA release was lower in DAlesioned animals administered Celexa relative to DA-denervated animals (p =
0.240) (a_b)- With DRN stimulation, release increased in both groups but
remained lower in the DA-depleted animals treated with Celexa (p = 0.132)
(a_a). Values represent the mean ± SEM and expressed as pg DA/pl MannWhitney U Test was utilized to analyze the data. N = 6 in each group.
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Figure 4. Comparison Between the Effects of Serotonin Depletion and Serotonin Reuptake
Inhibition on Striatal Dopamine Release.
Effect of 5-HT lesioning was determined by comparing basal and stimulationevoked DA release in the absence and presence of L-dopa in DA-lesioned
animals treated with Celexa and DA + 5-HT-lesioned animals. In the absence of
exogenous L-dopa, basal DA release did not differ among DA-lesioned animals
relative to the DA + 5-HT-denervated group (p = 0.138) (b_b)- Stimulationevoked DA release was significantly greater in DA-lesioned animals treated with
Celexa compare to DA + 5-HT-lesioned animals (p = 0.014) (b_a). Subsequent to
L-dopa treatment, basal DA release significantly increased in DA-lesioned
animals treated with Celexa relative to DA + 5-HT-depleted animals (p = 0.001)
(a_b)- With DRN stimulation, DA release increased in both groups but remained
significantly increased in DA-depleted animals administered Celexa (p = 0.035)
(a_a). Values represent the mean ± SEM and expressed as pg DA/pl. MannWhitney U Test was utilized to analyze the data. P < 0.01 is indicated by ** and
P < 0.05 by *. N = 6 and 7.
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3.4. Comparison Between the Effects of Striatal Intemeuron Lesioning and Serotonin
Reuptake Inhibition on Striatal Dopamine Release
Animals receiving both a DA-lesion within the MFB and a striatal intemeuron
lesioned described in Chapter 3 were compared to DA-depleted animals treated with
Celexa. Both basal (p = 0.699) (b_b) and stimulation-evoked (p = 0.485) (b_a) DA release,
in the absence of exogenous L-dopa, did not differ between the DA-lesioned + Celexa
group and animals with a combined 6-OHDA + quinolinic acid (QA)-lesion (Figure 5).
However, in the presence of L-dopa, the concentration of DA increased significantly
among the doubled-lesioned (6-OHDA + QA) group relative to the DA + Celexa animals
(p = 0.026) (a_b)- Release was further significantly increased subsequent to DRN
stimulation in 6-OHDA + QA-treated animals compared to DA-denervated animals
administered Celexa (p = 0.002) (a_a).
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Figure 5. Comparison Between the Effects of Striatal Intemeuron Lesioning and Serotonin
Reuptake Inhibition on Striatal Dopamine Release.
Effect of striatal intemeuron lesioning was determined by comparing basal and
stimulation-evoked DA release in the absence and presence of L-dopa in DAlesioned animals treated with Celexa and 6-OHDA + QA-lesioned animals. In
the absence of exogenous L-dopa, both basal (p = 0.699) (b_b) and stimulationevoked (p = 0.485) (b_a) DA release did not differ between the DA-lesioned
and 6-OHDA + QA-depleted animals. Subsequent to L-dopa treatment, basal
DA release was significantly increased (p = 0.026) in 6-OHDA + QA-lesioned
relative to DA-depleted + Celexa treated animals (a_b)- With DRN stimulation,
release was even greater in 6-OHDA + QA-lesioned animals (p = 0.002) (a_a).
Values represent the mean ± SEM and expressed as pg DA/pl. MannWhitney U Test was utilized to analyze the data. P < 0.01 is indicated by **
and P < 0.05 by *. N = 6 in each group.
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4. Discussion
This study shows that following prolonged DA depletion, striatal DA release after
exogenous L-dopa is reduced in the presence of the selective serotonin reuptake inhibitor,
Celexa. Basal and stimulation-evoked DA release prior to L-dopa administration did not
differ between DA-depleted animals treated with the SSRI and DA-lesioned animals from
Chapter 2. Among DA-depleted animals treated with Celexa, more than a five-fold increase
in DA release resulted subsequent to L-dopa administration relative to the DA-denervated
group. With DRN stimulation, release was increased in both groups, but the extracellular
DA concentration was significantly lower in DA-lesioned animals administered the SSRI.
Apomorphine testing indicated that both groups of animals were severely DA-depleted.
Thus, the groups differed only by the presence of Celexa during the experiment.
To investigate the effect of Celexa on DA release from exogenous L-dopa in the
non-denervated animals, DA-lesioned animals treated with the SSRI were compared to DA
sham-lesioned and naiVe animals also administered Celexa. In the presence of L-dopa,
basal DA release did not differ between the three groups. However, with DRN stimulation
following L-dopa administration, DA release increased only in the DA-depleted group,
whereas release remained relatively unchanged in the non-denervated groups. The nearly
three-fold increase in stimulation-evoked DA release among the experimental animals
compared to control groups (sham-lesioned and naive) suggests the possibility that striatal
5-HT innervation differs between the three groups.
To further investigate striatal 5-HT terminals, DA-lesioned animals treated with
Celexa were compared to the group of DA-denervated animals also deficient of striatal
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5-HT from Chapter 2. Subsequent to exogenous L-dopa application, there was an eleven
fold increase in basal DA release in the DA-depleted group administered Celexa relative to
the DA and 5-HT-lesioned animals. Although DA release was increased in both groups in
the presence of L-dopa with DRN stimulation, DA concentration was significantly greater
in the Celexa-treated, DA-denervated animals. The increased stimulation-evoked DA
release among the DA + 5-HT-depleted animals may have been due to incomplete 5-HT
lesioning. Even if a few remaining 5-HT terminals were present, they were unable to
significantly increase basal DA release. Collectively, our findings indirectly suggest 5-HT
nerve terminals as the major contributor to DA synthesis from exogenous L-dopa following
prolonged DA depletion. However, Celexa is capable of reducing the DA released from
these 5-HT terminals.
For decades it has remained a mystery where L-dopa is converted to DA in the
parkinsonian patient. If a patient can remain asymptomatic until DA depletion exceeds 80%
[20], how can L-dopa administration supplement the deficiency with a significant reduction
in the number of DA neurons. In fact, some patients can respond to L-dopa therapy for
many years providing support for non-dopaminergic neurons as a site of DA conversion
from exogenous L-dopa.
Miller et al. [30] have demonstrated a small increase in striatal DA release
subsequent to exogenous administration of L-dopa in animals with intact dopaminergic
systems. The increase was much larger among animals that were DA-denervated.
Following administration of the DA reuptake transporter inhibitor, GBR-12909, the
elevated basal DA release was enhanced in intact animals but no change occurred in DAdenervated animals. These findings further support the likelihood that non-dopaminergic
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neurons within the STR are responsible for DA synthesis from applied L-dopa in the DAdeficient rat.
The synthesis of DA from administered L-dopa is dependent upon the presence of
the enzyme AADC and its requirements, iron, oxygen, and tetrahydrobiopterin [reviewed
in 2, reviewed in 47]. 5-HT terminals also contain AADC since 5-HT synthesis from its
precursor, 5-hydroxytryptophan (5-HTP), requires this enzyme [5, 6, 28]. Prior
investigations have determined the AADC located in 5-HT terminals to be identical to
AADC in DA neurons [24, 29, 51]. The only difference that exists is the greater affinity of
AADC for L-dopa than for 5-HTP. Moreover, 5-HT terminals have been shown to contain
DA following exogenous L-dopa administration [5, 33]. Presumably the L-dopa enters the
5-HT neurons through a specific carrier for large neutral amino acids (LNAAs), as it is
thought to occur as L-dopa crosses the blood-brain barrier and also enters DA neurons
[reviewed in 47].
5-HT afferents that originate from the DRN innervate the STR [3, 17, 21, 39, 41,
45]. Although striatal 5-HT innervation is significantly less than DA input in the intact
animal [13], there is evidence of serotonergic hyperinnervation subsequent to striatal DA
denervation. This phenomenon is well accepted to occur in adult rats neonatally-depleted of
DA [1,19, 23, 25, 36, 40,41,44]. However, some controversy exists as to whether the 5HT hyperinnervation occurs when the nigrostriatal dopaminergic system is lesioned in
adult rats [16, 50] and non-human primates [15]. It is clear that 5-HT hyperinnervation does
not occur until there is at least 90 to 95% striatal DA denervation [16]. Also, this effect of
hyperinnervation is not seen less than 1 month [39] to 2 months [16] subsequent to DA
denervation.
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The occurrence of 5-HT hyperinnervation within the DA-denervated STR and
demonstration of the capability of 5-HT terminals to take up L-dopa and convert it to DA
support the likelihood that 5-HT neurons are a source of DA production from administered
L-dopa. In a previous study, we demonstrated that animals with prolonged DA-depletion
have a four-fold increase in extracellular DA release subsequent to L-dopa administration
relative to control groups. With DRN stimulation, release was further increased. However,
the increased DA release was eliminated in DA-depleted animals also having a striatal 5HT lesion. This indirectly suggests serotonergic terminals that hyperinnervate the DAdenervated STR are important in determining the availability of DA for interaction with
target neurons in the STR in the presence of L-dopa. We interpreted our results to show
that 5-HT nerve terminals are the primary sites for DA synthesis from administered Ldopa.
The substantial increase in basal DA release we observed in the presence of L-dopa
in DA-lesioned animals indirectly suggests that release was not regulated in the same
manner as control animals (sham-lesioned and naive). It is possible that L-dopa is not only
entering the 5-HT neurons through the LNAA transporters, but also through SERT. DA can
be taken up by SERT [11], but it has a low affinity for DA [18] and probably a low affinity
for L-dopa as well. However, with the administration of L-dopa in the event of prolonged
DA-depletion, a large extracellular L-dopa concentration accumulates. Degradative
enzymes in the synaptic cleft may be overwhelmed and there may be too few LNAA
transporters to carry the large amount of L-dopa into the cell. Consequently, L-dopa may
also be transported by SERT. Application of Celexa likely prohibited a portion of L-dopa
from entering the terminal through SERT for subsequent DA synthesis and release. This
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may explain why we saw reduced basal DA release subsequent to Celexa administration in
DA-depleted rats treated with L-dopa. Further studies are necessary to confirm the validity
of this hypothesis.
In the presence of exogenous L-dopa, Celexa administration in DA-depleted
animals resulted in a 80% reduction in basal extracellular DA concentration compared to
DA-depleted animals not treated with the SSRI. Celexa is highly selective for SERF, with
no to low affinity for the 5-HTiA and 5-HT2a receptors [35]. This suggests that the actions
of Celexa are the result of interactions with the transporter and not due to a decrease in
firing activity or subsequent changes in release through the actions of 5-HT receptor
subtypes. In an intact animal we would expect administration of a 5-HT or DA reuptake
blocker to result in increased synaptic 5-HT or DA concentration, respectively, which
blocks the inhibition of further transmitter release. However, we did not see this. Rather
when the SERT transporter was blocked, there was a reduction in DA release.
Having such a high extracellular DA concentration may lead to reverse DA
transport back into the 5-HT terminals via SERT. To protect and conserve the releasable
vesicular pool of transmitter, DA may be taken up by vesicular monoamine transporter
(VMAT2). Once compartmentalized, DA may interact with an osmotically inert matrix to
maintain a certain concentration of vesicular DA. However, the DA or 5-HT concentration
within the vesicle may become too high and may compete with vesicular 5-HT for binding
to the inert matrix. Consequently, DA or 5-HT may passively flow out into the cytoplasm
where it is potentially toxic to 5-HT terminals. Administration of a serotonin reuptake
inhibitor may limit the amount of DA that can re-enter the 5-HT terminal by reducing the
amount of L-dopa transported into the cell, thus protecting the neuron from potentially
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cytotoxic effects of a high concentration of cytoplasmic DA. This hypothesis is purely
hypothetical and also requires further experimentation to determine the validity of the
rationale.
In conclusion, this study demonstrated that Celexa reduces basal DA release
derived from exogenous L-dopa in animals with prolonged DA depletion. This has
important implications for understanding the mechanism by which L-dopa is effective in
the treatment of PD and possibly its toxic effects with chronic use in this disease.

NOTE: This study was sponsored by the Department of the Army (cooperative agreement
number DAMD17-97-2-7016). The content of the information does not necessarily reflect
the position or the policy of the government or NMTB, and no official endorsement should
be inferred.
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CHAPTER FIVE
INTEGRATIVE DISCUSSION AND CONCLUSIONS

1. Dissertation Findings and Discussion
Although L-dopa is the most potent and effective drug available to treat Parkinson’s
disease (PD) [2, 12,41], it remains unknown how DA is produced from its administered
precursor when there is severe DA neuron loss [23, 26, 38, 40, 42]. The objective of the
experiments performed for this dissertation was to address the most likely sites where DA
conversion from exogenous L-dopa could occur. At present, remaining DA neurons [23],
dorsal raphe serotonergic terminals [3, 4, 5, 23, 29, 38] and striatal intemeurons [23, 24] are
the most likely sites. In this dissertation, each of these sites were examined by selective
lesioning of neurons and DA release was measured using microdialysis. The experiments
performed indirectly suggest the majority of DA synthesis from exogenous L-dopa takes
place in serotonergic terminals that hyperinnervate the DA-denervated striatum.

1.1 Striatal Dopamine-Denervation Using 6-Hydroxydopamine (6-OHDA)
DA-denervation was attained in the experiments by injecting 6-OHDA within the
left or the right medial forebrain bundle (MFB), the major afferent pathway of DAcontaining neurons from the substantia nigra pars compacta (SNc). To assay the
effectiveness of DA lesioning, apomorphine, a DA agonist, was administered. Supersentive
DA postsynaptic receptors on the side of the 6-OHDA injection cause the animals to rotate
contralateral to the side of the lesion [16]. Animals that centralaterally rotate 6 or more
times per minute over 15 minutes were included in the experimental groups [10].
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Basal DA release measured using microdialysis could not be utilized to determine
the severity of the 6-OHDA lesion. This is because the DA concentration measured in the
dialysates only reflect the released DA that escaped enzymatic breakdown within the
synaptic cleft. This required the use of apomorphine testing to address the loss of striatal
DA content. The concentration of 6-OHDA and stereotaxic coordinates used for the lesion
were identical to the protocol utilized by Carlson et al. [10] where an average of 97.5%
striatal DA loss was reported. Therefore, it is likely that the experimental animals included
in the studies performed had an approximate 97.5% striatal DA depletion.

1.2 Effect of Dopamine Lesioning on Striatal Dopamine Release
Basal DA release prior to L-dopa administration was reduced in DA-depleted
animals relative to sham-lesioned and naive control animals. Further analysis using a posthoc test indicated that DA release was significantly lower in 6-OHDA-lesioned animals
than the naive control animals but not the sham-lesioned. Without L-dopa present,
stimulation-evoked DA release was also reduced in the experimental animals compared to
both control groups. However, post-hoc analysis revealed a statistical difference only
between the DA-depleted animals and the naive control group. The extracellular DA
concentration during dorsal raphe nucleus (DRN) stimulation decreased relative to basal in
all three groups which was expected because of the inhibitory action of serotonin (5-HT)
neurons that innervate the SNc.
Subsequent to L-dopa administration, basal DA release was increased 83% and
71% in DA depleted animals with respect to sham-lesioned and control groups,
respectively. Despite the substantial loss in DA neurons, an elevated extracellular DA
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concentration was measured following L-dopa application. This indirectly suggests another
site may be responsible for DA release.
Although 6-OHDA lesioning in the experimental animals resulted in severe DA
depletion, some DA neurons remained. The possibility of homotypic sprouting subsequent
to the 6-OHDA lesion cannot be completely ruled out in this group of animals since
apomorphine testing was not performed a second time 6 to 9 months post-60HDA
lesioning in this group (i.e., prior to microdialysis). Apomorphine re-testing was performed
in another group of 6-OHDA-lesioned animals prior to receiving a quinolinic acid (QA)
lesion (Chapter 3). All six of these animals remained severely DA depleted. It is possible
that homotypic sprouting may have occurred in the double-lesioned animals, however it
was minimal as suggested by the apomorphine challenge. Also, the mean DA concentration
measured in the 6-OHDA and QA-lesioned animals (0.07128 pg DA/jul) was not
significantly different from animals having only the DA lesion (0.07167 pg DA/pl).
Although DA release measured using microdialysis does not depict striatal DA content,
release of DA was similar between the two groups.
DA neurons have been shown to increase their firing activity, increase synthesis
and release of DA, and down-regulate reuptake receptors in an effort to increase
extracellular DA [27, 43] following severe DA depletion. On this premise, despite
experimental animals being severely DA-depleted, the possibility that remaining DA
neurons have the capability to compensate for the significant reduction in quantity of DA
terminals cannot be completely ignored. It would seem unlikely that the few remaining DA
neurons could be responsible for the substantial increase in basal DA release following Ldopa administration we observed. We would expect to see extracellular DA concentrations

141

similar to or less than levels measured in the sham-lesioned or naive control groups if
remaining DA neurons were solely responsible for the conversion. Instead a large increase
in DA release occurred. Although it does not appear to be likely, further
electrophysiological studies are necessary to determine the capacity of DA turnover in an
individual DA neuron.
During DRN stimulation in the presence of L-dopa, more than a four-fold increase
in extracellular DA among DA-lesioned animals compared to both of the control groups
(sham-lesioned and naive) occurred. These results are contrary to what we saw prior to Ldopa application. Under normal conditions, stimulation of the DRN would result in reduced
striatal DA release because of the inhibition of dopaminergic neurons by serotonergic
afferents in the SNc. The significantly elevated stimulation-evoked DA release relative to
basal in the experimental and control (sham-lesioned and naive) groups treated with L-dopa
suggests that serotonergic dorsal raphe terminals may be capable of DA synthesis from its
administered precursor.

1.3 Effect of Serotonin Lesioning on Striatal Dopamine Release
To investigate the possible contribution of 5-HT terminals in DA production from
administered L-dopa, DA-denervated animals also received a focal 5-HT lesion. In the
absence of exogenous L-dopa, there was nearly a ten-fold decrease in basal DA release
among DA + 5-HT-lesioned animals relative to the sham-lesioned and naive control
groups. Prior to L-dopa application, stimulation-evoked DA release in experimental
animals remained significantly reduced compared to the control animals (sham-lesioned
and naive). DA release was reduced from basal in all three groups during DRN stimulation.
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These results were expected because of the inhibitory actions of 5-HT afferents that
innervate the SNc.
Subsequent to L-dopa administration, basal DA release was 94.4 % and 93.6 %
lower among the double-lesioned animals compared to sham-lesioned and naive control
groups, respectively. This comparison does not reveal whether the difference in DA release
between the groups was the result of DA terminal depletion or 5-HT terminal loss.
However, the results from animals having only the DA lesion (Chapter 2) suggest that 5HT terminals may be important for enhanced DA release from its administered precursor.
Although extracellular DA release with DRN stimulation remained significantly
lower in DA + 5-HT-depleted animals with respect to controls (sham-lesioned or naive) in
the presence of exogenous L-dopa, release increased in all of the groups relative to basal.
This is opposite to what we would expect. It is possible that electrical stimulation of the 5HT afferents projecting to the striatum increased the firing rate of the 5-HT neurons
resulting in an increase in the exogenous L-dopa-derived pool of DA available for release.
The increased stimulation-evoked DA release observed in DA + 5-HT-lesioned animals
subsequent to L-dopa treatment may suggest that the 5-HT lesion was incomplete. This
cannot be ruled out since measures to determine the severity of the 5-HT lesion were not
taken. However, any 5-HT terminals that may have remained were not sufficient enough to
increase DA release to the level seen in the other groups unless they were electrically
stimulated. These results suggest that in the presence of the DA precursor, activation of 5HT terminals are able to enhance DA release.
To further evaluate the consequence of the 5-HT lesion in DA-depleted animals,
comparisons of extracellular DA concentrations in these animals were made with animals
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having only the DA lesion. Prior to application of the DA precursor, basal and stimulationevoked DA release did not differ statistically between the two experimental groups.
However, following L-dopa application, basal DA release was 98 % greater in DAdepleted animals relative to animals with the combined DA and 5-HT-lesion. Although
under DRN stimulation DA release increased in both groups, the extracellular DA
concentration remained significantly higher in DA-denervated group with respect to the
double-lesioned animals. The two groups of DA-denervated animals differed only with
respect to the 5-HT lesion which resulted in diminished basal and stimulated DA release.
These results suggest that 5-HT terminals are important for the enhanced DA release when
L-dopa is present.
If the presence of striatal serotonergic terminals is important for DA synthesis, then
why was DA release (basal and stimulation-evoked) with exogenous L-dopa substantially
increased only in the DA-denervated group but not in the DA sham-lesioned or control
animals, all of which had intact serotonergic systems? Is it possible that striatal 5-HT
innervation is altered following severe, chronic DA depletion?
It is well established that in adult rats neonatally-depleted of DA, serotonergic
hyperinnervation of the DA-denervated striatum occurs over a period of 2 to 9 months [1,
15, 18, 33, 35, 36, 39]. Immunohistochemical analysis reveals an increase in 5-HT fiber
density without increased 5-HT turnover [21]. However, Snyder et al [35] was not able to
demonstrate the occurrence of striatal hyperinnervation 2 weeks and 1 month following DA
denervation using 6-OHDA in neonatal rats suggesting that the time period following the
lesion is an important factor. Some controversy exists as to whether the 5-HT
hyperinnervation results when the nigrostriatal dopaminergic system is lesioned in adult
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rats [13, 22, 37, 44]. The conflicting findings in studies performed in adult rats appear to be
due to the elapsed time between the 6-OHDA lesion and subsequent analysis. Studies
demonstrating 5-HT hyperinnervation [13, 44] waited 2 to 4 months post-DA denervation.
Investigations not observing this pattern of hyperinnervation allowed only 2 weeks [22, 37]
which likely was not sufficient time for any neuroplastic changes to occur in response to
the injury.
If 5-HT neurons do not have the necessary machinery for DA synthesis from
exogenous L-dopa, then the occurrence of increased 5-HT fiber density subsequent to
prolonged DA depletion is pointless toward understanding where DA conversion occurs.
5-HT synthesis from its precursor 5-hydroxytryptophan (5-HTP) requires the enzyme
amino acid decarboxylase (AADC) [5, 6, 20, 25, 41, 45]. This enzyme is also necessary for
DA production from L-dopa [5, 6, 20, 25, 29, 41, 45]. The AADC located in 5-HT
terminals has been demonstrated to be identical to AADC found in DA neurons [20, 25,
45], with the only difference being the greater affinity of AADC for L-dopa than for 5HTP. This point is further supported by the observation that 5-HT terminals have been
shown to contain DA following exogenous L-dopa administration [3, 29]. Collectively,
these findings provide additional indirect support for 5-HT terminals as the primary site
where DA synthesis from exogenous L-dopa occurs following DA-denervation.

1.4 Effect of Striatal Intemeuron Lesioning on Striatal Dopamine Release
Striatal QA injections were applied to DA-denervated animals to investigate the
possible participation of striatal intemeurons in the conversion of administered L-dopa to
DA. Prior to L-dopa administration, basal DA release was significantly reduced in the DA
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+ QA-lesioned group compared to the sham-lesioned and naive control animals. Post-hoc
testing revealed that DA release in experimental animals was significantly reduced only
with respect to the naive control group. During DRN stimulation in the absence of L-dopa,
DA release was also reduced in the DA + QA-lesioned group relative to the control groups,
although not significantly. Simulation-evoked DA release was reduced from basal in all
three groups as expected from the inhibitory 5-HT afferents in the SNc.
Following L-dopa treatment, basal DA release was increased in the DA + QAlesioned animals 88 % and 76 % compared to sham-lesioned and control animals,
respectively. Release was increased in all groups with DRN stimulation contradictory to
what is expected from activation of the inhibitory 5-HT neurons that innervate the SNc.
These results indirectly suggest that DA synthesis from its applied precursor occurs in the
absence of striatal intemeurons and striatal DA terminals.
Apomorphine testing of the experimental group 2 weeks post-6-OHDA lesion and 8
to 16 months post-6-OHDA lesion indicated that these animals were and remained severely
DA-depleted. Also, the severity of the QA lesion was assessed in the experimental animals
by re-testing them 1 week following the QA lesioning [31, 32]. Only the rats having less
than 3 rotations/min, contralateral to the side of the lesion over a period of 15 minutes were
included in the experimental group. All of the DA + QA-lesioned animals tested met the
qualification. Because the above comparisons of DA release were made in animals both
depleted of DA and striatal intemeurons, the individual contribution of both sites in DA
conversion from exogenous L-dopa cannot be estimated.
To assess the paricipation of striatal intemeurons as a possible conversion site, DA
release in DA + QA-lesioned animals was compared to animals having only a DA lesion.
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Basal and stimulation-evoked DA release was nearly the same prior to L-dopa
administration. However, in the presence of L-dopa, basal and stimulation-evoked DA
release was increased 35 % and 21 %, respectively, among the DA-depleted group with
respect to DA + QA-lesioned animals. The differences were not statistically significant
which may have resulted from the large variance among the animals having only the DA
lesion. The elevated variance in these animals is likely to have occurred because of the
learning curve associated with all of the techniques employed in the experiments.
The results indirectly suggest that striatal intemeurons do contribute to some of the
DA release after exogenous L-dopa treatment in severely DA-depleted rats. Striatal
intemeurons contain AADC providing a potential site where DA conversion from L-dopa
can occur. However, whether the striatal intemeurons act as a source of releasable DA or
through their influence on other cells in the striatum cannot be conclusively determined
from the experiments performed in this dissertation.

1.5 Effect of Serotonin Reuptake Inhibition on Striatal Dopamine Release
If the majority of DA produced from its administered precursor occurs within 5-HT
terminals that hyperinnervate the DA-denervated striatum, what would the effect of a
serotonin reuptake inhibitor (SSRI) have on DA release? It was our hypothesis that
application of a SSRI would reduce the DA release in DA-denervated animals treated with
L-dopa.
To investigate this, extracellular DA concentration was compared between DAdepleted animals, DA sham-lesioned, and control animals all treated with Celexa, a SSRI.
Prior to L-dopa administration, basal and stimulation-evoked DA release was significantly
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reduced in DA-depleted animals compared to the sham-lesioned and naive control animals.
However, subsequent to Celexa and L-dopa treatment, basal DA release did not differ
between the three groups. With DRN stimulation following Celexa and L-dopa application,
DA release increased from basal only in the DA-depleted group, whereas release remained
relatively unchanged in the non-denervated groups.
Under normal conditions, application of a SSRI would block extracellular 5-HT re
entry into the 5-HT terminal. Consequently, a higher extracellular 5-HT concentration
results for a period of time before diffusion or enzymatic breakdown. Celexa is selective
for serotonin reuptake transporters (SERT) with minimal effects on DA transporters (DAT)
or norepinephrine transporters (NET) [11, 30]. Therefore, it is unlikely that Celexa
seriously affected catecholamine-containing neurons. Following Celexa and L-dopa
administration, we did not see an increase in basal DA release in the DA-denervated
animals with respect to both control groups. However, in the presence of the SSRI and DA
precursor, electrical stimulation of 5-HT neurons resulted in an increased DA release only
in the experimental animals where levels remained unchanged in both control groups. It is
not clear why the stimulation-evoked DA release was relatively the unchanged from basal
in the sham-lesioned and naive control animals.
To further evaluate the effect of Celexa on exogenously L-dopa-derived DA
release, DA-denervated animals were compared to DA-depleted animals treated with the
SSRI. In the absence of L-dopa, basal and stimulation-evoked DA release was not
significantly different between the two groups. However, subsequent to L-dopa application,
more than a five-fold decrease in basal DA release was measured in the DA-depleted
animals treated with Celexa with respect to the DA-lesioned group. With DRN stimulation
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in the presence of L-dopa, DA release was increased in both groups, but the extracellular
DA concentration remained lower in DA-lesioned animals administered Celexa. These
results demonstrate that DA release is reduced in the presence of Celexa in DA-depleted
animals treated with L-dopa.
Although the SSRI was capable of reducing the amount of basal and stimulationevoked DA released, it did not diminish extracellular DA levels as much as animals having
both a DA and 5-HT lesion. In fact, subsequent to L-dopa administration, basal DA release
was increased by 91 % in DA-depleted animals treated with Celexa relative to DA + 5-HTlesioned animals. We would not expect Celexa treatment to have an effect equal to 5-HT
lesioning unless the Celexa was capable of blocking all L-dopa transport.
The importance of Celexa use in conjunction with L-dopa is due to its ability to
reduce DA release to the levels measured in control animals. Without Celexa present, basal
DA release subsequent to L-dopa treatment in DA-depleted animals was substantially
increased compared to DA sham-lesioned and naive control groups. Celexa is highly
selective for SERT, with no to low affinity for the 5-HTia and S-HTia receptors [30]. This
suggests that the actions of Celexa are the result of interactions with the transporter and not
due to a decrease in firing activity or subsequent changes in release through the actions of
5-HT receptor subtypes. In an intact animal we would expect administration of a reuptake
inhibitor to result in increased synaptic transmitter concentration. However, this was not
observed. Rather when SERT was blocked, there was a reduction in DA release.
It is possible that L-dopa is not only entering the 5-HT neurons through the large
neutral amino acid (LNAA) transporter, but also through SERT. DA can be taken up by
SERT [11], but it has a low affinity for DA [14] and probably a low affinity for L-dopa as
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well. However, with exogenous L-dopa administration, a high extracellular concentration
of L-dopa accumulates. There may be too few LNAA transporters to carry the L-dopa into
the neuron. Consequently, because of the increased concentration gradient, L-dopa may
also be transported by SERT into the cell. Application of Celexa possibly prohibited a
portion of L-dopa from entering the terminal through SERT for subsequent DA synthesis
and release. Thus DA release was maintained at a level comparable to control groups. This
hypothesis is completely speculative. Further studies are necessary to confirm the validity
of the rationale. The use of striatal synaptosomes bearing SERT and LNAA transporters in
the presence of [3H] L-dopa and/or Celexa is one possibility for investigating this
hypothesis.
The significance of the reduced DA release following Celexa administration in DAdenervated, L-dopa treated animals is that it may protect 5-HT terminals from
accumulating excessive free DA. It is plausible that the increased extracellular DA level
reaches such high concentrations that the degradative enzymes become overwhelmed.
Consequently, more DA is available to interact with postsynaptic receptors or is capable of
reverse transport through SERT. Although the affinity for DA is low, the high
concentration gradient may override the transporter selectivity.
Intraneuronal DA may accumulate as more transmitter undergoes reverse transport
down its concentration gradient. To reduce the concentration of cytoplasmic DA, the
vesicular monoamine transporter (VMAT2) actively transports DA into vesicles where it is
free to interact with the osmotically inert matrix. The competition between
compartmentalized DA and 5-HT for binding to the matrix may result in increased
vesicular DA concentrations allowing DA to passively flow out into the cytoplasm. As
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more DA accumulates in the terminal, the degradative enzyme, MAOa (monoamine
oxidase A), may become overwhelmed allowing for free DA or 5-HT to remain in the
cytoplasm where it is potentially toxic to 5-HT terminals. The effect of Celexa may be two
fold. It may limit L-dopa uptake exclusively to the LNAA transporters and also prevent too
much extracellular DA from entering the 5-HT terminal where it is potentially cytotoxic.
This hypothesis is purely hypothetical and also requires further experimentation (e.g.,
striatal synaptosomes) to determine the validity of the rationale.

2.

Clinical Implications and Conclusions
Although performed in rats, the results from this study are important for

understanding L-dopa therapy in humans. Clinicians have been perplexed for decades how
patients with severe DA depletion can be relieved of their debilitating symptoms through
administration of L-dopa, the precursor of DA. In fact, patients are responsive to L-dopa
therapy for many years before treatment becomes ineffective and evidence of additional
neurotransmitter deficiencies present. With the majority of DA neurons lost at the time of
diagnosis, how can L-dopa be effective? Since L-dopa cannot act on postsynaptic DA
receptors [41], DA conversion from exogenous L-dopa must occur. Where does this
conversion take place?
Our findings support the hypothesis that in the event of severe DA depletion, dorsal
raphe serotonergic terminals that innervate the striatum are primarily responsible for DA
production from exogenous L-dopa. This finding possibly explains why many PD patients
are responsive to L-dopa treatment for many years. Furthermore, in the later stages of PD,
patients (untreated and L-dopa treated) present symptoms related to 5-HT loss (e.g.,
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depression, sleep disorders, memory problems, anxiety) [2, 9, 12, 19, 34, 41, 42]. This
alludes to the likelihood that 5-HT neurons are also affected in the disease process
independent of L-dopa treatment.
This dissertation demonstrates a marked increase in basal DA release among Ldopa treated, DA-denervated animals which leads to the speculation that this is neurotoxic
to striatal 5-HT terminals that participate in the DA synthesis. Consequently, 5-HT neuron
loss may be potentiated by chronic treatment with L-dopa. Application of a SSRI was able
to reduce the basal DA release which may attenuate the potentially cytotoxic effect of DA
to 5-HT terminals. Thus the use of SSRIs in conjunction with L-dopa therapy could
potentially be neuroprotective to 5-HT terminals in the patient with PD who are treated
with Sinemet.

152

References
[1] Abrous, D. N., M. Manier, F. Mennicken, C. Feuerstein, M. Le Moal, and J. P.
Herman. Intrastriatal transplants of embryonic dopaminergic neurons counteract the
increase of striatal enkephalin immunostaining but not serotonergic sprouting elicited by a
neonatal lesion of the nigrostriatal dopaminergic pathway. European Journal of
Neuroscience. 5 (1993) 128-136.
[2] Adler, C. H. and J. E. Ahlskog. Parkinson’s disease and movement disorders. Humana
Press, New Jersey 2000.
[3] Arai, R., N. Karasawa, M. Geffard, T. Nagatsu, and I. Nagatsu.
Immunohistochemical evidence that serotonin neurons produce dopamine from
exogenous L-dopa in the rat, with reference to the involvement of aromatic L-amino acid
decarboxylase. Brain Research. 667 (1994) 295-299.
[4] Arai, R., N. Karasawa, M. Geffard, and I. Nagatsu. L-dopa is converted to dopamine in
serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study.
Brain Research. 195 (1995) 195-198.
[5] Arai, R., N. Karasawa, and I. Nagatsu. Aromatic L-amino acid decarboxylase is present
in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence
study. Brain Research. 706 (1996) 177-179.
[6] Berry, M. D., A. V. Juorio, X-M. Li, and A. A. Boulton. Aromatic L-amino acid
decarboxylase: a neglected and misunderstood enzyme. Neurochemical Research. 21(9)
(1996) 1075-1087.
[7] Breese, G. R., G. E. Duncan, T. C. Napier, S. C. Bondy, L. C. lorio, and R. A. Mueller.
6-Hydroxydopamine treatments enhance behavioral responses to intracerebral
microinjection of Dl- and D2-dopamine agonists into nucleus accumbens and striatum
without changing dopamine antagonist binding. Journal of Pharmacology and Experimental
Therapeutics. 240 (1987) 167-176.
[8] Bruno, J. P., D. Jackson, M. J. Zigmond, and E. M. Strieker. Effects of dopaminedepleting brain lesions in rat pups: role of striatal serotonergic neurons in behavior.
Behavioral Neuroscience. 101 (1987) 806-811.
[9] Caley, C. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. The
Annals of Pharmacotherapy. 31 (1997) 1481-1489.
[10] Carlson, J. D., R. D. Pearlstein, J. Buchholz, R. P. lacono, and G. Maeda. Regional
metabolic changes in the pedunculopontine nucelus of unilateral 6-hydroxydopamine
Parkinson’s model rats. Brain Research. 828 (1998) 62-68.

153

[11] Cass, W. A., N. R. Zahniser, K.A. Flach, and G. A. Gerhart. Clearance of exogenous
dopamine in rat dorsal striatum and nucleus accumbens: Role of metabolism and effects of
locally applied uptake inhibitors. Journal of Neurochemistry. 61 (1993) 2269-2278.
[12] Clark, C. M. and J. Q. Trojanowski. Neurodegenerative dementias. Me Graw Hill,
New York, 2000.
[13] Guerra, M. J., I. Liste, and J. L. Labandeira-Garcia. Effects of lesions of the
nigrostriatal pathway and of nigral grafts on striatal serotonergic innervation in adult rats.
Neuro Report. 8 (1997) 3485-3488.
[14] Hoffman, B. J., E. Mezey, and M. J. Brownstein. Cloning of a serotonin transporter
affected by antidepressants. Science. 254 (1991) 579-580.
[15] Jackson, D. and E. D. Abercrombie. In vivo neurochemical evaluation of striatal
serotonergic hyperinnervation in rats depleted of dopamine at infancy. Journal of
Neurochemistry. 58(3) (1992) 890-897.
[16] Jankovic, J. and E. Tolosa. Parkinson’s disease and movement disorders. 4th Edition.
Williams and Wilkens, Baltimore, 2002.
[17] Kang, U. J., D. H. Park, T. Wessel, H. Baker, and T. H. Joh. DOPA-decarboxylation
in the striata of rats with unilateral substantia nigra lesions. Neuroscience Letters. 147
(1992) 53-57.
[18] Kostrzewa, R. M., T. A. Reader, and L. Descarries. Serotonin neural adaptations to
ontogenetic loss of dopamine neurons in rat brain. Journal of Neurochemistry. 70 (1998)
889-898.
[19] Liu, H., R. P. lacono, T. Schoonenberg, S. Kuniyoshi, and J. Buchholz. A
comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson’s
disease. Neurobiology of Disease. 6 (1999) 35-42.
[20] Lovenberg, W., H. Weissbach, and S. Udenfriend. Aromatic L- amino acid
decarboxylase. The Journal of Biological Chemistry. 237(1) (1962) 89-93.
[21] Luthman, J., B. Bolioli, T. Tsutsumi, A. Verhofstad, and G. Jonsson. Sprouting of
striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine
neurons in the neonatal rat. Brain Research Bulletin. 19 (1987) 269-274.
[22] Melamed, E., F. Hefti, J. Liebman, A. J. Schlosberg, and R. J. Wurtman.
Serotonergic neurones are not involved in action of L-dopa in Parkinson’s disease.
Nature. 283 (1980) 772-774.

154

[23] Melamed, E., F. Hefti, and R. J. Wurtman. Nonaminergic striatal neurons convert
exogenous L-dopa to dopamine in Parkinsonism. Annals of Neurology. 8 (1980) 558563.
[24] Melamed, E., F. Hefti, and R. J. Wurtman. Diminished decarboxylation of L-dopa
in rat striatum after intrastriatal injections of kainic acid. Neuropharmacology. 19 (1980)
409-411.
[25] Melamed, E., F. Hefti, and R. J. Wurtman. L-3,4-dihydroxyphenylalanine and L-5hydroxytryptophan decarboxylase activities in rat striatum: effect of selective destruction
of dopaminergic or serotonergic input. Journal of Neurochemistry. 34(6) (1980) 17531756.
[26] Miller, D. W. and E. D. Abercrombie. Role of high-affinity dopamine uptake and
impulse activity in the appearance of extracellular dopamine in striatum after exogenous Ldopa administration: studies in intact and 6-hydroxydopmaine-treated rats. Journal of
Neurochemistry. 72(4) (1999) 1516-1522.
[27] Mura, A., D. Jackson, M. S. Manley, S. J. Young, and P. M. Groves. Aromatic Lamino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the
conversion of exogenous L-dopa to dopamine. Brain Research. 704 (1995) 51-60.
[28] Nakazato, T. and A. Akiyama. Decarboxylation of exogenous L-3,4dihydroxyphenylalanine in rat striatum as studied by in vivo voltammetry. Journal of
Neurochemistry. 58 (1992) 121-127.
[29] Ng, L. K. Y., R. W. Colburn, and I. J. Kopin. Effects of L-dopa on accumulation and
efflux of monoamines in particles of rat brain homogenates. The Journal of Pharmacology
and Experimental Therapeutics. 183(2) (1972) 316-325.
[30] Physician’s Desk Reference, 56 Edition. Medical Economic Company, Inc., New
Jersey, 2002.
[31] Puschban, Z., C. Scherfler, R. Granata, P. Laboyrie, N. P. Quinn, P. Jenner, W.
Poewe, and G. K. Wenning. Autoradiographic study of striatal dopamine re-uptake sites
and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double
lesion rat model of striatonigral degenergation (multiple system atrophy) and effects of
embryonic ventral mesencephalic, striatal or co-grafts. Neuroscience. 95(2) (2000) 377388.
[32] Puschban, Z., R. Waldner, K. Seppi, N. Stefanova, C. Humpel, C. Scherfler, M.
Levivier, W. Poewe, and G. K. Wenning. Failure of neuroprotection by embryonic striatal
grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy).
Experimental Neurology. 164(1) (2000) 166-175.

155

[33] Reader, T. A., F. Radja, K. M. Dewar, and L. Descarries. Denervation,
hyperinnervation, and interactive regulation of dopamine and serotonin receptors. Annals
of the New York Academy of Sciences. 757 (1995) 293-310.
[34] Steur, E.N. Increase of parkinson disability after fluoxetine medication. Neurology.
43(1) (1993) 211-213.
[35] Snyder, A. M., M. J. Zigmond, and R. D. Lund. Sprouting of serotoninergic afferents
into striatum after dopamine-depleting lesions in infant rats: a retrograde transport and
immunocytochemical study. Journal of Comparative Neurology. 245 (1986) 274-281.
[36] Stachowiak, M. K., J. P. Bruno, A. M. Snyder, E. M. Strieker, and M. J. Zigmond.
Apparent sprouting of striatal serotonergic terminals after dopamine-depleting lesions in
neonatal rats. Brain Research. 291 (1984) 164-167.
[37] Takeuchi, Y., T. Sawada, S. Blunt, P. Jenner, and C. D. Marsden. Effects of 6hydroxydopamine lesions of the nigrostriatal pathwasy on striatal serotonin innervation in
adult rats. Brain Research. 562 (1991) 301-305.
[38] Tanaka, H., K. Kannari, T. Maeda, M. Tomiyama, T. Suda, and M. Matsunaga. Role
of serotonergic neurons in L-dopa-derived extracellular dopamine in the striatum of 6OHDA-lesioned rats. NeuroReport. 10 (1999) 631-634.
[39] Towle, A. C., H. E. Criswell, E. H. Maynard, J. M. Lauder, T. H. Joh, R. A. Mueller,
and G. R. Breese. Serotonergic innervation of the rat caudate following a neonatal 6hydroxydopamine lesion: an anatomical, biochemical and pharmacological study.
Pharmacology, Biochemistry, and Behavior. 34 (1989) 367-374.
[40] Wachtel, S. R. and E. D. Abercrombie. L-3,4-dihydroxyphenylalanine-induced
dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential
effects of monoamine oxidase A and B inhibitors. Journal of Neurochemistry. 63(1) (1994)
108-117.
[41] Webster, R. A. Neurotransmitters, drugs, and brain function. John Wiley and Sons,
Chichester, 2001.
[42] Yamato, H., K. Kannari, H. Shen, T. Suda, and M. Matsunaga. Fluoxetine reduces Ldopa-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport. 12 (8)
(2001) 1123-1126.
[43] Zhong, X. FL, J. W. Haycock, K. Shannak, Y. Robitaille, J. Fratkin, A. H. Koeppen,
O. Homykiewicz, and S. J. Kish. Striatal dihydroxyphenylalanine decarboxylase and
tyrosine hydroxylase protein in idiopathic Parkinson’s disease and dominantly inherited
olivopontocerebellar atrophy. Movement Disorders. 10(1) (1995) 10-17.

156

[44] Zhou, F. C., S. Bledsoe, and J. Murphy. Serotonergic sprouting is induced by
dopamine-lesion in substantia nigra of adult rat brain. Brain Research. 556 (1991) 108-116.
[45] Zhu, M-Y. and A. V. Juorio. Aromatic L-amino acid decarboxylase: biological
characterization and functional role. General Pharmacology. 26(4) (1995) 681-696.

157

APPENDIX I - MICRODIALYSIS PROBE CONSTRUCTION
1. Take stainless steel tubing (24 gauge, thin wall)
Cut 30 mm and 8 mm segments using a dremel drill with a round, fine cutter.
Using the face of the cutter, file off the ends of the segments.
Using a 22 gauge needle, clear the opening of the segments and thread through a
thin wire to ensure there is no blockage.

o:

D
30 mm

I 8 mm

Cut
2. Take the 30 mm segment and bend one end, approximately 8 mm from the end.
- Using the face of the cutter, nick the curvature of the bend but do not cut
completely through the tubing.
With a 22 gauge needle, clear away hole and thread through a wire to ensure there
is no blockage.

o:

o:

Nick
3. Using a scalpel blade, cut silica tubing into segments of 25 mm and 50 mm.
Thread the 50 mm segment of silica tubing through the 8 mm stainless steel tubing
with approximately 10 mm of the silica tubing from one end of the stainless steel.
- Using a 25 gauge needle, apply Krazy glue to both ends of the stainless steel to
prevent the silica tubing from moving. Allow 30 minutes to dry.
A'

n

A

u

t t

Apply Krazy Glue
4. Take the 30 mm stainless steel segment that has been bent and thread the 25 mm piece
of silica tubing. Allow for approximately 10 mm of silica tubing from the bent end of
the stainless steel.

o:
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5. Take the 8 mm piece of stainless steel with the attached silica tubing and insert into the
hole of the 30 mm piece of stainless steel.

o:

cfc.

"A

6. Apply epoxy to the intersection and allow several hours to dry.

o:

A

7. With the scalpel blade, trim the silica tubing to 3 mm.

t

o:

Cut
8. Cut the dialysis membrane into segments of 10 mm.
Using needle nose forceps, insert the membrane over the silica and into the stainless
steel tubing.

n
9. With a 25 gauge needle, apply a very, small quantity of epoxy to the tip of the
membrane. Allow several minutes to dry.

P

Epoxy
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10. With the flat surface of the scalpel blade, push the end of the membrane into the
stainless steel tubing so that there is 0.5 to 1 mm between the end of the silica tubing
and the epoxy tip of the membrane.
Apply epoxy to the end of the stainless steel tubing and allow it to slightly run onto
the beginning of the membrane.
Smooth off epoxy to prevent excess.
Allow to dry overnight.
Outlet
4 mm
f ■■■■

Inlet

%■■■■

Epoxy
11. Test the probe for proper functioning before implanting into the brain. Take an ethanol
filled syringe filled with a blunt 22 gauge needle and attach FEP tubing. Hook the
tubing to the inlet and perfuse the probe at a rate of 10 pl/min. The high flow rate will
firm the membrane and remove any glycerol.
Check to see that the ethanol comes out the outlet only. The probe is not good if
ethanol comes out anywhere other than the outlet or if it does not come out at all.
Hook the FEP tubing to the outlet. If condensation looks like it is forming on the
outside of the membrane, the probe is not working properly. Do not use it.
Once a good probe has been identified, inspect it for air bubbles. With FEP tubing
connected to the inlet and outlet of the probe, shine light directly onto the
membrane. If sparkles appear during perfusion, air is trapped in the membrane.
Repeatedly tap the stainless steel tubing very carefully to move the air out of the
probe. If air remains trapped, recovery will be severely affected.
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